patient_id string | sex string | age_at_diagnosis_years float64 | diabetes_duration_years float64 | current_age_years float64 | race_ethnicity string | insurance_type string | bmi_kg_m2 float64 | weight_kg float64 | height_cm float64 | waist_circumference_cm float64 | waist_hip_ratio float64 | body_fat_pct float64 | visceral_fat_index float64 | hba1c_baseline_pct float64 | hba1c_current_pct float64 | hba1c_at_target_flag int64 | hba1c_above_9_flag int64 | fasting_glucose_mgdl float64 | postprandial_glucose_mgdl float64 | fasting_insulin_uIU_ml float64 | homa_ir float64 | homa_b_pct float64 | c_peptide_ng_ml float64 | beta_cell_function_pct float64 | total_cholesterol_mgdl float64 | ldl_mgdl float64 | hdl_mgdl float64 | triglycerides_mgdl float64 | non_hdl_cholesterol_mgdl float64 | uric_acid_mgdl float64 | crp_mg_l float64 | alt_iu_l float64 | ast_iu_l float64 | ggt_iu_l float64 | adiponectin_ug_ml float64 | leptin_ng_ml float64 | thyroid_tsh_uIU_ml float64 | sbp_mmhg float64 | dbp_mmhg float64 | hypertension_flag int64 | hypertension_medication string | pharmacotherapy_line string | metformin_flag int64 | metformin_dose_mg_day int64 | metformin_hba1c_reduction_pct float64 | sglt2_inhibitor_flag int64 | sglt2i_drug string | sglt2i_hba1c_reduction_pct float64 | sglt2i_weight_loss_kg float64 | sglt2i_sbp_reduction_mmhg float64 | uti_on_sglt2i_flag int64 | glp1_agonist_flag int64 | glp1_drug string | glp1_hba1c_reduction_pct float64 | glp1_weight_loss_kg float64 | glp1_nausea_flag int64 | glp1_vomiting_flag int64 | dpp4_inhibitor_flag int64 | dpp4i_drug string | dpp4i_hba1c_reduction_pct float64 | sulfonylurea_flag int64 | sulfonylurea_drug string | su_hypoglycemia_events_per_year int64 | su_weight_gain_kg float64 | thiazolidinedione_flag int64 | insulin_flag int64 | insulin_type string | basal_insulin_units_per_day float64 | total_daily_insulin_units float64 | insulin_hba1c_reduction_pct float64 | insulin_weight_gain_kg float64 | medication_adherence_pct float64 | polypharmacy_count int64 | diet_pattern string | diet_quality_score float64 | caloric_intake_kcal_day float64 | carbohydrate_pct_intake float64 | fiber_g_day float64 | saturated_fat_pct float64 | exercise_type string | exercise_frequency_per_week int64 | exercise_minutes_per_session float64 | sedentary_hours_per_day float64 | vo2max_ml_kg_min float64 | sleep_hours_per_night float64 | sleep_quality_score float64 | ahi_events_per_hour float64 | obstructive_sleep_apnea_flag int64 | smoking_status string | pack_years float64 | alcohol_drinks_per_week int64 | stress_score float64 | weight_loss_intervention_flag int64 | weight_change_kg_1yr float64 | lifestyle_hba1c_modifier_pct float64 | diabetes_stage string | insulin_resistance_index float64 | retinopathy_stage string | retinopathy_tte_years float64 | egfr_ml_min_173m2 float64 | uacr_mg_g float64 | microalbuminuria_flag int64 | macroalbuminuria_flag int64 | ckd_flag int64 | esrd_flag int64 | diabetic_neuropathy_flag int64 | neuropathy_type string | dnss_score int64 | mace_flag int64 | cad_flag int64 | stroke_flag int64 | heart_failure_flag int64 | peripheral_arterial_flag int64 | nafld_flag int64 | nash_flag int64 | cirrhosis_flag int64 | dyslipidemia_flag int64 | statin_flag int64 | statin_intensity string | depression_flag int64 | phq9_score int64 | cognitive_decline_flag int64 | podiatric_complication_flag int64 | bg_monitoring_frequency_per_day float64 | cgm_use_flag int64 | cgm_device string | diabetes_education_flag int64 | endocrinology_referral_flag int64 | pcp_visits_per_year int64 | foot_exams_per_year int64 | eye_exams_per_year int64 | diabetes_distress_score float64 | self_efficacy_score float64 | health_literacy_score float64 | social_support_score float64 | financial_toxicity_flag int64 | data_sku string | seed int64 | generated_at string |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
HC002-0000001 | Female | 69.2 | 12.4 | 81.6 | White | Medicare | 32.3 | 81.8 | 159.3 | 69.5 | 0.852 | 37.1 | 2.6 | 7.1 | 5.7 | 1 | 0 | 105.3 | 178.1 | 33.2 | 8.63 | 64.2 | 2.53 | 26.4 | 176 | 88.7 | 49.9 | 187 | 126.1 | 4.6 | 4.38 | 168.8 | 129.6 | 93.6 | 6.7 | 40.1 | 2.42 | 136 | 89 | 1 | Beta_blocker | Dual | 1 | 1,000 | 1.17 | 0 | null | 0 | 0 | 0 | 0 | 0 | null | 0 | 0 | 0 | 0 | 0 | null | 0 | 1 | Glyburide_5mg | 2 | 2.5 | 0 | 0 | null | 0 | 0 | 0 | 0 | 65.4 | 8 | Low_carb | 72.9 | 1,434 | 29.5 | 19.1 | 14.3 | Aerobic | 2 | 46 | 6.2 | 23 | 7.2 | 4.9 | 16 | 1 | Never | 0 | 4 | 5.9 | 0 | -2.3 | -0.63 | Uncontrolled | 8.63 | Severe_NPDR | 8.1 | 49 | 200.1 | 1 | 0 | 1 | 0 | 1 | Autonomic | 4 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 1 | Moderate | 1 | 14 | 1 | 0 | 1 | 0 | null | 0 | 0 | 3 | 2 | 0 | 0.99 | 8 | 6.7 | 6.4 | 1 | HC-END-002 | 42 | 2026-05-29T12:51:29Z |
HC002-0000002 | Male | 53.1 | 4.3 | 57.4 | Hispanic | Private | 37 | 117.9 | 178.4 | 90 | 0.901 | 38.2 | 6.2 | 8.6 | 5.5 | 1 | 0 | 200 | 349.5 | 60 | 25 | 127.4 | 6.06 | 73.1 | 229.6 | 114.7 | 20 | 474.8 | 209.6 | 5.3 | 14.88 | 105.8 | 62.6 | 58.2 | 10.9 | 25.5 | 1.98 | 132 | 79 | 1 | Thiazide | Dual | 1 | 1,500 | 1.35 | 0 | null | 0 | 0 | 0 | 0 | 1 | Dulaglutide_1.5mg | 1.66 | 8.5 | 1 | 0 | 0 | null | 0 | 0 | null | 0 | 0 | 1 | 0 | null | 0 | 0 | 0 | 0 | 68.9 | 8 | Western | 69.4 | 2,182 | 46.6 | 17.5 | 15.4 | Resistance | 5 | 30 | 7.9 | 29.7 | 5.7 | 4.5 | 36.4 | 1 | Current | 5.7 | 5 | 5.5 | 0 | 9.6 | -1.05 | Uncontrolled | 25 | null | 3.6 | 71.5 | 87.3 | 1 | 0 | 0 | 0 | 0 | null | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 1 | Moderate | 1 | 15 | 0 | 0 | 0 | 0 | null | 1 | 1 | 4 | 1 | 1 | 0.49 | 3.2 | 2.9 | 6.5 | 1 | HC-END-002 | 42 | 2026-05-29T12:51:29Z |
HC002-0000003 | Female | 59 | 4.2 | 63.1 | Black | Medicare | 20.6 | 50.9 | 157.2 | 65 | 0.889 | 17.3 | 2 | 9.1 | 8.5 | 0 | 0 | 138.6 | 202.2 | 45.1 | 15.43 | 145.9 | 5.68 | 69 | 228.1 | 50 | 38 | 907.3 | 190.1 | 5.7 | 5.07 | 44.4 | 43.7 | 70.4 | 8.6 | 53 | 1.8 | 173 | 100 | 1 | ACEi | Dual | 0 | 0 | 0 | 0 | null | 0 | 0 | 0 | 0 | 0 | null | 0 | 0 | 0 | 0 | 0 | null | 0 | 1 | Glyburide_5mg | 2 | 3.2 | 0 | 0 | null | 0 | 0 | 0 | 0 | 77.5 | 6 | Low_carb | 67.5 | 1,839 | 23.3 | 21 | 13.5 | null | 0 | 8 | 7.3 | 17.9 | 7.4 | 2.2 | 10.6 | 1 | Never | 0 | 5 | 6.1 | 1 | -6.2 | -0.62 | Uncontrolled | 15.43 | Mild_NPDR | 2.3 | 103.6 | 52.6 | 1 | 0 | 0 | 0 | 0 | null | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | null | 1 | 16 | 0 | 0 | 5 | 0 | null | 1 | 0 | 2 | 0 | 2 | 2.24 | 6.3 | 4.7 | 5.9 | 1 | HC-END-002 | 42 | 2026-05-29T12:51:29Z |
HC002-0000004 | Female | 51.3 | 30 | 81.3 | White | Private | 46.8 | 114 | 156 | 101.8 | 0.908 | 56.6 | 7.3 | 7.8 | 5.5 | 1 | 0 | 135.2 | 250.5 | 29.4 | 9.82 | 2.1 | 0.31 | 1.9 | 160.6 | 73.6 | 49.2 | 188.8 | 111.4 | 4.1 | 3.55 | 99.3 | 63.1 | 64.1 | 10.5 | 49 | 5.85 | 133 | 93 | 1 | Combination | Complex | 0 | 0 | 0 | 0 | null | 0 | 0 | 0 | 0 | 1 | Liraglutide_1.2mg | 1.41 | 1.9 | 1 | 0 | 0 | null | 0 | 0 | null | 0 | 0 | 0 | 1 | Premixed | 30.5 | 50.2 | 1.21 | 2.8 | 67.9 | 7 | Mixed | 57.8 | 1,533 | 47 | 15.4 | 6.4 | null | 0 | 0 | 10.7 | 15 | 7.2 | 4.5 | 25.7 | 1 | Never | 0 | 3 | 5.5 | 0 | -3.5 | -0.64 | Uncontrolled | 9.82 | DME | 3.9 | 48.3 | 172.9 | 1 | 0 | 1 | 0 | 1 | Autonomic | 3 | 0 | 1 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 0 | null | 1 | 6 | 1 | 0 | 4 | 0 | null | 1 | 0 | 3 | 3 | 0 | 4.28 | 9.5 | 9.8 | 10 | 1 | HC-END-002 | 42 | 2026-05-29T12:51:29Z |
HC002-0000005 | Male | 50 | 1.1 | 51.1 | Hispanic | Medicaid | 32.3 | 84.5 | 161.7 | 75 | 1.049 | 28.6 | 0.6 | 9.7 | 7.8 | 0 | 0 | 196.3 | 307.4 | 20.1 | 9.73 | 125.9 | 5.94 | 72.2 | 245.6 | 175.4 | 33.3 | 184.2 | 212.3 | 4.9 | 6.14 | 63.4 | 41.5 | 102 | 6 | 22.4 | 1.81 | 182 | 91 | 1 | ARB | Monotherapy | 1 | 1,500 | 0.96 | 0 | null | 0 | 0 | 0 | 0 | 1 | Liraglutide_1.2mg | 1.65 | 7.3 | 0 | 0 | 0 | null | 0 | 1 | Glipizide_10mg | 3 | 1.6 | 0 | 0 | null | 0 | 0 | 0 | 0 | 68.7 | 7 | Mixed | 39.4 | 2,684 | 43.3 | 8 | 11.9 | null | 0 | 0 | 10.8 | 22.8 | 6.7 | 4.7 | 5.8 | 0 | Never | 0 | 2 | 4.9 | 0 | -7.3 | -0.18 | Controlled | 9.73 | null | 2.7 | 79 | 23.7 | 0 | 0 | 0 | 0 | 0 | null | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | Moderate | 1 | 13 | 0 | 0 | 3 | 0 | null | 1 | 0 | 7 | 4 | 2 | 3.61 | 5.6 | 8.4 | 7.4 | 0 | HC-END-002 | 42 | 2026-05-29T12:51:29Z |
HC002-0000006 | Female | 42.6 | 10.3 | 53 | Black | Uninsured | 39 | 97.8 | 158.3 | 84.9 | 0.882 | 49.9 | 7.1 | 8.6 | 6.4 | 1 | 0 | 134.1 | 235.7 | 41.9 | 13.87 | 75.9 | 3.49 | 43.1 | 186.7 | 102.5 | 42.4 | 209 | 144.4 | 6.5 | 5.53 | 63.9 | 30.6 | 28.7 | 7.3 | 38.3 | 1.92 | 156 | 76 | 1 | Beta_blocker | Triple | 0 | 0 | 0 | 1 | Dapagliflozin_10mg | 1.3 | 2.9 | 3.7 | 0 | 0 | null | 0 | 0 | 0 | 0 | 1 | Alogliptin_25mg | 1.15 | 0 | null | 0 | 0 | 0 | 1 | Basal_only | 45.8 | 82.3 | 3.37 | 0 | 43.3 | 9 | DASH | 85.6 | 1,574 | 35.7 | 22.8 | 9 | Aerobic | 2 | 50 | 7.5 | 29.2 | 7.3 | 4.1 | 18 | 1 | Former | 60 | 3 | 4.2 | 0 | -2.1 | 0.3 | Uncontrolled | 13.87 | Mild_NPDR | 2 | 104.7 | 117.6 | 1 | 0 | 0 | 0 | 1 | Peripheral | 4 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 1 | High | 0 | 4 | 0 | 0 | 3 | 1 | DexcomG7 | 0 | 0 | 3 | 2 | 1 | 1.96 | 3.4 | 9.1 | 6.5 | 0 | HC-END-002 | 42 | 2026-05-29T12:51:29Z |
HC002-0000007 | Female | 57.2 | 30 | 87.2 | Black | Private | 33 | 80 | 155.8 | 73.5 | 0.915 | 39.4 | 4 | 9.7 | 7.4 | 0 | 0 | 231.6 | 460.9 | 52.4 | 25 | 0 | 0.31 | 0 | 186.9 | 50 | 27.8 | 685.5 | 159.1 | 4.9 | 9.84 | 53.2 | 28.3 | 33.4 | 10.6 | 50.6 | 1.63 | 175 | 79 | 1 | Beta_blocker | Triple | 1 | 2,000 | 1.04 | 1 | Empagliflozin_10mg | 0.31 | 2.3 | 3.6 | 0 | 0 | null | 0 | 0 | 0 | 0 | 1 | Linagliptin_5mg | 0.3 | 1 | Glimepiride_4mg | 3 | 3.1 | 0 | 1 | Basal_bolus | 39.7 | 51 | 3.42 | 3.4 | 50.1 | 8 | Western | 30.5 | 2,257 | 54.2 | 8 | 14 | null | 0 | 5 | 7.8 | 15.2 | 7.6 | 3.5 | 42.8 | 1 | Current | 14.5 | 6 | 5.7 | 0 | 1.4 | 0.27 | Uncontrolled | 25 | DME | 18.9 | 55.8 | 298.9 | 1 | 0 | 1 | 1 | 1 | Peripheral | 3 | 1 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 1 | 1 | Moderate | 0 | 2 | 0 | 0 | 0 | 0 | null | 0 | 0 | 7 | 1 | 2 | 6 | 8.4 | 7.6 | 8.8 | 0 | HC-END-002 | 42 | 2026-05-29T12:51:29Z |
HC002-0000008 | Female | 41.8 | 5.5 | 47.2 | Asian | Medicare | 24.5 | 57.2 | 152.6 | 65 | 0.842 | 26.6 | 1.8 | 8.7 | 7.6 | 0 | 0 | 158.9 | 209.1 | 42.8 | 16.81 | 121.2 | 5.47 | 61 | 188.8 | 50 | 64.3 | 384.9 | 124.4 | 4.9 | 6.28 | 53 | 35.7 | 23.5 | 13.4 | 22.6 | 2.24 | 160 | 83 | 1 | Thiazide | Monotherapy | 1 | 1,000 | 1.41 | 0 | null | 0 | 0 | 0 | 0 | 0 | null | 0 | 0 | 0 | 0 | 0 | null | 0 | 1 | Glipizide_5mg | 3 | 1.9 | 0 | 0 | null | 0 | 0 | 0 | 0 | 59.2 | 7 | Mixed | 64 | 1,764 | 40.9 | 14.1 | 10 | Aerobic | 4 | 36 | 7 | 29.6 | 7.9 | 3.8 | 20.3 | 1 | Never | 0 | 5 | 3.7 | 0 | 4.3 | -0.3 | Controlled | 16.81 | null | 5.5 | 67.2 | 258.6 | 1 | 0 | 0 | 0 | 0 | null | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 1 | 1 | Moderate | 0 | 5 | 0 | 0 | 3 | 0 | null | 1 | 0 | 3 | 1 | 0 | 1.3 | 6.5 | 7.1 | 9 | 0 | HC-END-002 | 42 | 2026-05-29T12:51:29Z |
HC002-0000009 | Male | 60 | 24 | 84 | White | Medicaid | 32.9 | 98.5 | 172.9 | 75.2 | 0.931 | 29.9 | 4.7 | 9 | 8.3 | 0 | 0 | 176.1 | 318.2 | 29 | 12.62 | 0 | 0.46 | 1.6 | 187.6 | 118.6 | 25 | 220 | 162.6 | 7 | 3.77 | 61.2 | 51.6 | 59.3 | 11.9 | 18.9 | 2.1 | 166 | 82 | 1 | ACEi | Dual | 1 | 500 | 0.38 | 0 | null | 0 | 0 | 0 | 0 | 0 | null | 0 | 0 | 0 | 0 | 0 | null | 0 | 0 | null | 0 | 0 | 0 | 0 | null | 0 | 0 | 0 | 0 | 46.9 | 4 | Mediterranean | 79.3 | 1,707 | 35.4 | 26.7 | 5.3 | null | 0 | 6 | 8.9 | 29.8 | 6.9 | 4 | 33.5 | 1 | Never | 0 | 3 | 3.2 | 0 | -2.2 | -0.51 | Insulin_requiring | 12.62 | PDR | 12.7 | 18.7 | 380 | 0 | 1 | 1 | 0 | 0 | null | 0 | 1 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 1 | High | 1 | 15 | 0 | 0 | 5 | 0 | null | 1 | 0 | 5 | 0 | 0 | 3.57 | 6.1 | 8.6 | 7.7 | 0 | HC-END-002 | 42 | 2026-05-29T12:51:29Z |
HC002-0000010 | Male | 65 | 5.3 | 70.3 | Asian | Private | 33 | 110 | 182.7 | 82.8 | 0.988 | 29.2 | 1.5 | 7.4 | 6.1 | 1 | 0 | 126.7 | 184.5 | 45.3 | 14.19 | 114.6 | 4.92 | 59.6 | 100 | 50 | 21 | 299.7 | 79 | 5.4 | 16.81 | 102.9 | 85.4 | 24.5 | 6.3 | 18.5 | 1.33 | 177 | 99 | 1 | Thiazide | Monotherapy | 0 | 0 | 0 | 1 | Canagliflozin_100mg | 0.99 | 3.4 | 2.8 | 0 | 0 | null | 0 | 0 | 0 | 0 | 0 | null | 0 | 0 | null | 0 | 0 | 0 | 0 | null | 0 | 0 | 0 | 0 | 57.7 | 5 | Western | 42.6 | 1,907 | 55.3 | 8 | 11.1 | Aerobic | 3 | 51 | 8.8 | 27.7 | 6.5 | 5.6 | 34.7 | 1 | Never | 0 | 4 | 6 | 0 | 4.5 | -0.74 | Insulin_requiring | 14.19 | null | 7.2 | 81.6 | 312 | 0 | 1 | 0 | 0 | 0 | null | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 1 | Moderate | 1 | 11 | 0 | 0 | 3 | 0 | null | 1 | 0 | 2 | 1 | 0 | 2.06 | 5.4 | 8.5 | 8.8 | 0 | HC-END-002 | 42 | 2026-05-29T12:51:29Z |
HC002-0000011 | Male | 56.4 | 30 | 86.4 | White | Medicaid | 32.4 | 103.7 | 178.9 | 78.8 | 0.937 | 28.8 | 2.5 | 7.4 | 5.5 | 1 | 0 | 149.8 | 232.4 | 87.3 | 25 | 9.1 | 0.1 | 0 | 178 | 76.5 | 29.3 | 360.7 | 148.7 | 5.6 | 13.25 | 105.2 | 73.5 | 40.2 | 7.1 | 20.8 | 1.82 | 137 | 86 | 1 | ARB | Dual | 1 | 1,000 | 0.83 | 0 | null | 0 | 0 | 0 | 0 | 0 | null | 0 | 0 | 0 | 0 | 0 | null | 0 | 0 | null | 0 | 0 | 0 | 1 | Basal_only | 37.5 | 48 | 2.8 | 4.7 | 83.3 | 7 | Western | 42.1 | 2,231 | 52.7 | 13.2 | 14.3 | null | 0 | 20 | 4.3 | 18.6 | 7.1 | 6.8 | 43.5 | 1 | Current | 20.9 | 0 | 7.5 | 0 | 0.8 | -1.46 | Uncontrolled | 25 | PDR | 11.5 | 34.2 | 377.4 | 0 | 1 | 1 | 1 | 1 | Both | 1 | 1 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 1 | High | 0 | 2 | 0 | 0 | 3 | 0 | null | 1 | 0 | 5 | 1 | 0 | 4.5 | 8 | 7.2 | 8 | 0 | HC-END-002 | 42 | 2026-05-29T12:51:29Z |
HC002-0000012 | Female | 48.6 | 2.1 | 50.7 | White | Medicare | 33.1 | 82.7 | 158 | 71.5 | 0.876 | 33.2 | 4.3 | 10.4 | 8.9 | 0 | 0 | 247.7 | 329.8 | 43.2 | 25 | 118.2 | 5.38 | 65.1 | 133.2 | 50 | 43.7 | 588.3 | 89.4 | 5.5 | 18.06 | 200 | 136.7 | 31.6 | 2.6 | 31.1 | 2.89 | 143 | 68 | 1 | Combination | Insulin_based | 1 | 1,000 | 1.16 | 0 | null | 0 | 0 | 0 | 0 | 0 | null | 0 | 0 | 0 | 0 | 0 | null | 0 | 0 | null | 0 | 0 | 0 | 0 | null | 0 | 0 | 0 | 0 | 90.9 | 7 | DASH | 74.7 | 2,009 | 42.9 | 19.3 | 6.5 | Aerobic | 4 | 43 | 5.5 | 31.6 | 8.2 | 7.1 | 15.9 | 1 | Never | 0 | 2 | 3.9 | 1 | -0.1 | -0.41 | Complication_burden | 25 | null | 2 | 90.9 | 58.9 | 1 | 0 | 0 | 0 | 0 | null | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | null | 0 | 3 | 0 | 0 | 4 | 0 | null | 1 | 0 | 1 | 1 | 1 | 2.64 | 5.1 | 6.7 | 6.9 | 0 | HC-END-002 | 42 | 2026-05-29T12:51:29Z |
HC002-0000013 | Female | 57.4 | 7.6 | 65 | White | Uninsured | 28.3 | 76 | 163.8 | 65 | 0.796 | 28.5 | 0 | 9.4 | 7.2 | 0 | 0 | 165.5 | 240.5 | 14.7 | 6.02 | 111.6 | 4.76 | 59.8 | 246.8 | 50 | 44 | 770.7 | 202.8 | 3.3 | 7.38 | 78.8 | 42.7 | 140.1 | 7.2 | 38.5 | 3.49 | 131 | 74 | 1 | Beta_blocker | Dual | 1 | 1,500 | 1.43 | 0 | null | 0 | 0 | 0 | 0 | 0 | null | 0 | 0 | 0 | 0 | 0 | null | 0 | 0 | null | 0 | 0 | 0 | 0 | null | 0 | 0 | 0 | 0 | 89.5 | 7 | Vegan | 78.4 | 1,752 | 47.7 | 19.6 | 5.5 | Mixed | 5 | 49 | 4.5 | 23.6 | 7.6 | 2.4 | 31.5 | 1 | Never | 0 | 2 | 4.3 | 0 | 1.5 | -0.91 | Complication_burden | 6.02 | null | 7.9 | 73.4 | 437.1 | 0 | 1 | 0 | 0 | 1 | Peripheral | 1 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | null | 0 | 2 | 0 | 0 | 2 | 0 | null | 1 | 0 | 4 | 1 | 2 | 2.47 | 9.1 | 8.6 | 8.9 | 0 | HC-END-002 | 42 | 2026-05-29T12:51:29Z |
HC002-0000014 | Female | 48.3 | 10.3 | 58.6 | Hispanic | Uninsured | 32.2 | 86.5 | 163.9 | 71.3 | 0.807 | 35.4 | 3 | 6.8 | 5.5 | 1 | 0 | 166.2 | 363.7 | 42.6 | 17.49 | 69.1 | 3.45 | 41.8 | 245.3 | 111.3 | 30.9 | 515.5 | 214.4 | 5.4 | 6.72 | 89.4 | 66.5 | 33.5 | 11.1 | 31.1 | 2.22 | 118 | 96 | 1 | Beta_blocker | Dual | 1 | 1,000 | 1.75 | 1 | Empagliflozin_25mg | 0.68 | 2.1 | 3.5 | 0 | 0 | null | 0 | 0 | 0 | 0 | 0 | null | 0 | 0 | null | 0 | 0 | 0 | 0 | null | 0 | 0 | 0 | 0 | 78.2 | 7 | Mixed | 61.6 | 1,611 | 39.2 | 13.7 | 14.1 | Aerobic | 6 | 39 | 4 | 30.4 | 6.4 | 2.8 | 60 | 1 | Never | 0 | 5 | 2.1 | 0 | 5.3 | 0.33 | Insulin_requiring | 17.49 | null | 15.5 | 80.3 | 127.6 | 1 | 0 | 0 | 0 | 1 | Peripheral | 5 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 1 | Moderate | 0 | 3 | 0 | 0 | 1 | 1 | Libre3 | 1 | 0 | 2 | 2 | 0 | 4.15 | 6.4 | 4.2 | 4.8 | 0 | HC-END-002 | 42 | 2026-05-29T12:51:29Z |
HC002-0000015 | Male | 63.2 | 19.5 | 82.8 | White | Private | 32.9 | 98.9 | 173.4 | 75.7 | 0.998 | 28.3 | 3.4 | 8.7 | 6.5 | 1 | 0 | 140.1 | 308 | 118.3 | 25 | 27.4 | 1.14 | 16.1 | 217.4 | 98.6 | 20 | 493.9 | 197.4 | 5.3 | 10.59 | 70.1 | 47.1 | 28.3 | 10.1 | 25.1 | 2.26 | 141 | 84 | 1 | Beta_blocker | Dual | 1 | 2,000 | 0.99 | 1 | Empagliflozin_25mg | 0.71 | 3.2 | 1.8 | 0 | 0 | null | 0 | 0 | 0 | 0 | 0 | null | 0 | 1 | Glipizide_10mg | 4 | 1.8 | 0 | 1 | Basal_only | 29.4 | 35.9 | 0.9 | 3.5 | 65.5 | 10 | Mixed | 41.3 | 2,847 | 47 | 13.1 | 8.5 | Resistance | 1 | 45 | 7.5 | 24.5 | 6.9 | 5.4 | 19.2 | 1 | Never | 0 | 4 | 2.9 | 0 | 1.2 | -0.52 | Complication_burden | 25 | Severe_NPDR | 16.5 | 74.6 | 75.9 | 1 | 0 | 0 | 0 | 0 | null | 0 | 0 | 1 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 0 | null | 0 | 0 | 0 | 0 | 2 | 0 | null | 1 | 0 | 5 | 2 | 0 | 2.57 | 8.2 | 5.8 | 4.8 | 0 | HC-END-002 | 42 | 2026-05-29T12:51:29Z |
HC002-0000016 | Male | 30 | 12.3 | 42.3 | White | Medicare | 42.8 | 143.2 | 183 | 102.8 | 1.013 | 40.2 | 8.2 | 5.5 | 5.5 | 1 | 0 | 113.6 | 221.3 | 21.4 | 6 | 67.2 | 2.04 | 24.5 | 175.9 | 112.8 | 29.1 | 170.5 | 146.8 | 7.2 | 5.75 | 38.6 | 37.1 | 80.3 | 5.4 | 33.9 | 1.87 | 186 | 82 | 1 | ARB | Dual | 1 | 2,000 | 1.43 | 1 | Canagliflozin_100mg | 0.64 | 2.8 | 3.2 | 0 | 1 | Semaglutide_0.5mg | 2.32 | 5 | 1 | 0 | 0 | null | 0 | 1 | Glimepiride_2mg | 5 | 3.1 | 0 | 0 | null | 0 | 0 | 0 | 0 | 87.4 | 7 | DASH | 65.1 | 2,820 | 45.2 | 20.3 | 6.3 | Aerobic | 7 | 45 | 4 | 44.3 | 8.8 | 7.4 | 10.4 | 0 | Current | 60 | 0 | 2.9 | 0 | -2.3 | 0.05 | Insulin_requiring | 6 | null | 18.9 | 29.2 | 174.1 | 1 | 0 | 1 | 0 | 0 | null | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 1 | High | 1 | 11 | 0 | 0 | 4 | 0 | null | 1 | 1 | 4 | 1 | 2 | 3.83 | 8 | 3.4 | 7.8 | 0 | HC-END-002 | 42 | 2026-05-29T12:51:29Z |
HC002-0000017 | Female | 48 | 21.9 | 69.9 | Black | Medicare | 30.3 | 84.2 | 166.7 | 65 | 0.801 | 32.4 | 0 | 7.5 | 5.5 | 1 | 0 | 147.1 | 272.2 | 37.8 | 13.71 | 21.5 | 0.36 | 8 | 146.7 | 62.2 | 46.7 | 188.9 | 100 | 5.8 | 7.17 | 50.1 | 32.3 | 163 | 14.7 | 61.4 | 1.75 | 150 | 99 | 1 | ACEi | Complex | 1 | 2,000 | 1.38 | 0 | null | 0 | 0 | 0 | 0 | 0 | null | 0 | 0 | 0 | 0 | 0 | null | 0 | 0 | null | 0 | 0 | 0 | 1 | Concentrated | 24.4 | 25.2 | 1.33 | 1.5 | 78.3 | 7 | Mixed | 67.6 | 1,376 | 46.3 | 12.4 | 14.4 | null | 0 | 10 | 8.2 | 17.4 | 7.7 | 3.4 | 13 | 0 | Never | 0 | 1 | 7.4 | 0 | 2.3 | -0.69 | Uncontrolled | 13.71 | PDR | 10.9 | 56.5 | 69.1 | 1 | 0 | 1 | 0 | 0 | null | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 1 | 1 | Moderate | 1 | 12 | 0 | 0 | 2 | 0 | null | 1 | 0 | 1 | 1 | 0 | 2.65 | 3.8 | 4.4 | 5.4 | 0 | HC-END-002 | 42 | 2026-05-29T12:51:29Z |
HC002-0000018 | Male | 30 | 2.2 | 32.2 | White | Private | 27.9 | 82.1 | 171.5 | 75 | 1 | 22 | 4.9 | 9.9 | 7.9 | 0 | 0 | 147.6 | 295.1 | 31.7 | 11.57 | 136.2 | 5.68 | 72.8 | 160 | 50 | 24.6 | 436.2 | 135.4 | 6.7 | 5.71 | 44.1 | 34.8 | 53.5 | 6.7 | 11.5 | 1.45 | 180 | 71 | 1 | Thiazide | Dual | 1 | 2,000 | 1.32 | 0 | null | 0 | 0 | 0 | 0 | 0 | null | 0 | 0 | 0 | 0 | 0 | null | 0 | 0 | null | 0 | 0 | 1 | 0 | null | 0 | 0 | 0 | 0 | 92 | 7 | Western | 37.1 | 2,869 | 47.6 | 15.2 | 13.4 | Aerobic | 3 | 41 | 6.5 | 34.5 | 7 | 4.8 | 23.5 | 1 | Never | 0 | 3 | 2 | 0 | 2.2 | -0.81 | Controlled | 11.57 | null | 8.2 | 73.1 | 76.8 | 1 | 0 | 0 | 0 | 0 | null | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 1 | High | 1 | 14 | 0 | 0 | 1 | 1 | Libre2 | 0 | 0 | 5 | 0 | 2 | 0 | 7.2 | 7 | 8.5 | 0 | HC-END-002 | 42 | 2026-05-29T12:51:29Z |
HC002-0000019 | Female | 34.1 | 22.8 | 56.9 | White | Private | 29.5 | 76.1 | 160.5 | 65.6 | 0.828 | 30.6 | 0.7 | 8.2 | 5.7 | 1 | 0 | 153.4 | 323.2 | 38.8 | 14.68 | 15.6 | 1.26 | 10.8 | 258.8 | 119.3 | 41.7 | 489 | 217.1 | 3.2 | 2.72 | 18.7 | 13.3 | 57.3 | 5.7 | 19.6 | 1.09 | 191 | 60 | 1 | Thiazide | Triple | 1 | 1,000 | 1.09 | 1 | Empagliflozin_25mg | 0.77 | 3.4 | 4.6 | 0 | 0 | null | 0 | 0 | 0 | 0 | 0 | null | 0 | 1 | Glipizide_10mg | 1 | 2.1 | 0 | 1 | Basal_bolus | 18.8 | 34 | 1.88 | 3 | 66 | 7 | Western | 31.1 | 1,911 | 47.5 | 8 | 14.1 | Aerobic | 1 | 50 | 9.4 | 26.5 | 8.2 | 3.4 | 6.8 | 1 | Current | 4.8 | 0 | 6.4 | 0 | 0.4 | -0.04 | Uncontrolled | 14.68 | Mild_NPDR | 18.1 | 52.3 | 175.3 | 1 | 0 | 1 | 0 | 0 | null | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | null | 0 | 4 | 0 | 0 | 2 | 1 | null | 1 | 1 | 3 | 1 | 0 | 5.82 | 5.7 | 8.2 | 7.3 | 0 | HC-END-002 | 42 | 2026-05-29T12:51:29Z |
HC002-0000020 | Female | 68.4 | 30 | 90 | White | Uninsured | 32.8 | 83.8 | 159.9 | 67 | 0.861 | 35.6 | 1 | 8.6 | 6.8 | 1 | 0 | 154.8 | 273.6 | 42.7 | 16.33 | 0 | 0.1 | 0 | 158.7 | 55.2 | 41 | 312.2 | 117.7 | 5 | 7.49 | 43 | 31.1 | 132.9 | 5.9 | 53.3 | 1.6 | 200 | 78 | 1 | Combination | Monotherapy | 1 | 1,500 | 0.94 | 1 | Canagliflozin_300mg | 1.12 | 2 | 4.9 | 0 | 0 | null | 0 | 0 | 0 | 0 | 0 | null | 0 | 0 | null | 0 | 0 | 0 | 0 | null | 0 | 0 | 0 | 0 | 76.3 | 7 | Western | 47.4 | 1,709 | 51.1 | 15.1 | 13.6 | Resistance | 7 | 38 | 5 | 21.8 | 6.1 | 4.5 | 12.3 | 0 | Current | 2.2 | 5 | 5 | 0 | 4.1 | -0.23 | Uncontrolled | 16.33 | DME | 29.3 | 46.1 | 485 | 0 | 1 | 1 | 0 | 1 | Both | 2 | 1 | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 1 | 1 | High | 1 | 9 | 1 | 0 | 3 | 0 | null | 1 | 1 | 6 | 2 | 2 | 3.53 | 7.5 | 10 | 10 | 0 | HC-END-002 | 42 | 2026-05-29T12:51:29Z |
HC002-0000021 | Female | 62.7 | 20.5 | 83.2 | White | Private | 33.3 | 78.7 | 153.8 | 78.9 | 0.945 | 40.3 | 1.1 | 5.5 | 5.5 | 1 | 0 | 84.9 | 113.1 | 72.3 | 15.16 | 28.3 | 1.2 | 14.3 | 100 | 50 | 42.9 | 634.3 | 70 | 3.7 | 5.37 | 156.3 | 113.7 | 104.3 | 4.5 | 24.2 | 3.3 | 187 | 89 | 1 | Thiazide | Monotherapy | 1 | 2,000 | 0.67 | 0 | null | 0 | 0 | 0 | 0 | 0 | null | 0 | 0 | 0 | 0 | 1 | Alogliptin_25mg | 0.76 | 0 | null | 0 | 0 | 0 | 0 | null | 0 | 0 | 0 | 0 | 82 | 5 | Low_carb | 72 | 1,724 | 18.7 | 15.9 | 13.4 | null | 0 | 0 | 5.6 | 16.2 | 7.2 | 3.6 | 16.1 | 1 | Never | 0 | 5 | 6.7 | 0 | -5.9 | -0.21 | Complication_burden | 15.16 | DME | 9.3 | 53 | 513.4 | 0 | 1 | 1 | 0 | 0 | null | 0 | 1 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 1 | High | 0 | 5 | 1 | 0 | 3 | 1 | Libre2 | 0 | 0 | 1 | 1 | 1 | 2.37 | 6.1 | 6.3 | 4.7 | 0 | HC-END-002 | 42 | 2026-05-29T12:51:29Z |
HC002-0000022 | Male | 43.4 | 5.5 | 48.9 | White | Medicare | 31.7 | 103.9 | 181.1 | 75 | 1.008 | 23.1 | 0.9 | 7.8 | 6.8 | 1 | 0 | 149.2 | 289.2 | 39.6 | 14.61 | 112.7 | 5.38 | 61.1 | 224.1 | 123.4 | 28.3 | 362.5 | 195.9 | 6.2 | 5.88 | 82.4 | 76.8 | 77.9 | 9.3 | 19.7 | 1.82 | 189 | 80 | 1 | Beta_blocker | Dual | 0 | 0 | 0 | 1 | Empagliflozin_25mg | 0.61 | 1.5 | 5.7 | 0 | 0 | null | 0 | 0 | 0 | 0 | 0 | null | 0 | 0 | null | 0 | 0 | 0 | 0 | null | 0 | 0 | 0 | 0 | 82.4 | 6 | Mixed | 34.4 | 2,481 | 45.5 | 8 | 6.9 | HIIT | 1 | 41 | 9.2 | 26.1 | 9.1 | 5.8 | 20.4 | 1 | Never | 0 | 2 | 7.8 | 0 | 2.1 | -0.46 | Complication_burden | 14.61 | null | 10.4 | 56.4 | 90.9 | 1 | 0 | 1 | 0 | 1 | Peripheral | 5 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 1 | High | 0 | 6 | 0 | 0 | 1 | 0 | null | 0 | 0 | 4 | 2 | 2 | 4.71 | 2.4 | 5.6 | 8.8 | 0 | HC-END-002 | 42 | 2026-05-29T12:51:29Z |
HC002-0000023 | Female | 34 | 3.3 | 37.2 | White | Medicaid | 43.1 | 108 | 158.3 | 96.1 | 0.908 | 49.1 | 5.2 | 8.9 | 7.9 | 0 | 0 | 165.2 | 361.2 | 87.9 | 25 | 143.9 | 6.4 | 73.5 | 242 | 54.2 | 41.9 | 729.8 | 200.2 | 2.3 | 10.17 | 72.8 | 47.2 | 49 | 6.2 | 49.3 | 1.88 | 155 | 64 | 1 | CCB | Insulin_based | 1 | 2,000 | 1.24 | 0 | null | 0 | 0 | 0 | 0 | 0 | null | 0 | 0 | 0 | 0 | 0 | null | 0 | 1 | Glyburide_5mg | 2 | 2.9 | 0 | 0 | null | 0 | 0 | 0 | 0 | 90.4 | 5 | Vegan | 83.8 | 2,381 | 48.1 | 18.8 | 5.6 | Resistance | 5 | 23 | 11.3 | 30.8 | 7.6 | 3 | 60 | 1 | Current | 4 | 1 | 5.4 | 0 | 3.4 | 0.07 | Uncontrolled | 25 | null | 5.6 | 55.5 | 95.4 | 1 | 0 | 1 | 0 | 1 | Peripheral | 5 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 1 | 1 | High | 1 | 13 | 0 | 0 | 1 | 0 | null | 0 | 0 | 6 | 0 | 0 | 1.45 | 7.8 | 6.3 | 5.8 | 0 | HC-END-002 | 42 | 2026-05-29T12:51:29Z |
HC002-0000024 | Female | 30 | 4.5 | 34.5 | White | Private | 28.2 | 68 | 155.3 | 65 | 0.975 | 29.9 | 0 | 9.1 | 7.2 | 0 | 0 | 162.5 | 248.9 | 33.8 | 13.58 | 105.3 | 5.19 | 59.4 | 248.1 | 127.9 | 41.6 | 392.6 | 206.4 | 3.3 | 13.7 | 79.6 | 61 | 75.7 | 9.9 | 41.1 | 1.87 | 149 | 95 | 1 | ACEi | Monotherapy | 1 | 500 | 1.08 | 0 | null | 0 | 0 | 0 | 0 | 1 | Semaglutide_0.5mg | 1.27 | 2.9 | 1 | 0 | 0 | null | 0 | 0 | null | 0 | 0 | 0 | 0 | null | 0 | 0 | 0 | 0 | 80.9 | 8 | Mixed | 51.6 | 1,922 | 39.7 | 12.6 | 11.1 | Aerobic | 6 | 43 | 8.2 | 35 | 8.7 | 2.9 | 27 | 1 | Never | 0 | 5 | 7.8 | 0 | -3.3 | -0.01 | Uncontrolled | 13.58 | null | 5.9 | 46.6 | 196.2 | 1 | 0 | 1 | 0 | 0 | null | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 1 | 1 | Moderate | 0 | 5 | 0 | 0 | 3 | 0 | null | 1 | 1 | 1 | 2 | 1 | 1.52 | 1.7 | 7 | 7.4 | 0 | HC-END-002 | 42 | 2026-05-29T12:51:29Z |
HC002-0000025 | Female | 45.5 | 1.8 | 47.3 | Black | Medicare | 38.6 | 104.6 | 164.6 | 85.7 | 0.818 | 44 | 4.7 | 9.9 | 7.5 | 0 | 0 | 176.7 | 303.5 | 34.1 | 14.86 | 107.1 | 5.13 | 60.4 | 224.5 | 124.7 | 32.8 | 335.1 | 191.7 | 6.5 | 4.59 | 27.5 | 20.8 | 29.1 | 5.3 | 78.3 | 3.85 | 153 | 84 | 1 | ACEi | Dual | 1 | 1,500 | 0.93 | 0 | null | 0 | 0 | 0 | 0 | 0 | null | 0 | 0 | 0 | 0 | 0 | null | 0 | 0 | null | 0 | 0 | 0 | 0 | null | 0 | 0 | 0 | 0 | 80.4 | 5 | Mediterranean | 80.5 | 1,470 | 38.9 | 22.2 | 6 | HIIT | 1 | 34 | 9.9 | 23.6 | 6.7 | 9 | 11 | 0 | Never | 0 | 1 | 8.6 | 0 | -3.4 | -1.71 | Complication_burden | 14.86 | null | 5.1 | 80.1 | 48.3 | 1 | 0 | 0 | 0 | 0 | null | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | null | 0 | 1 | 0 | 0 | 4 | 0 | null | 1 | 1 | 3 | 0 | 0 | 0.82 | 6.5 | 10 | 8.3 | 1 | HC-END-002 | 42 | 2026-05-29T12:51:29Z |
HC002-0000026 | Male | 75 | 15.6 | 90 | Other | Uninsured | 23.3 | 72 | 175.6 | 75 | 0.901 | 18.4 | 1.5 | 8.1 | 5.5 | 1 | 0 | 142.8 | 232.1 | 23.3 | 8.22 | 39.4 | 1.81 | 19.2 | 230.7 | 156.4 | 40 | 171.3 | 190.7 | 6.6 | 4.74 | 64.3 | 37 | 36.9 | 8.3 | 39.6 | 1.45 | 148 | 90 | 1 | CCB | Dual | 0 | 0 | 0 | 1 | Canagliflozin_100mg | 0.94 | 1.9 | 4.9 | 0 | 1 | Semaglutide_1.0mg | 2.42 | 7.9 | 1 | 0 | 1 | Linagliptin_5mg | 0.43 | 0 | null | 0 | 0 | 0 | 1 | Basal_bolus | 43.6 | 86.3 | 2.72 | 4.8 | 62.1 | 9 | Low_carb | 62.1 | 1,668 | 27.9 | 13.2 | 12.7 | null | 0 | 0 | 8.6 | 15 | 6.2 | 4.2 | 60 | 1 | Never | 0 | 5 | 8.2 | 0 | 4 | -0.55 | Insulin_requiring | 8.22 | Severe_NPDR | 10.3 | 71.5 | 189.2 | 1 | 0 | 0 | 0 | 0 | null | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | Moderate | 0 | 2 | 0 | 0 | 0 | 1 | Libre3 | 1 | 0 | 4 | 0 | 0 | 2.52 | 10 | 6.5 | 7.6 | 0 | HC-END-002 | 42 | 2026-05-29T12:51:29Z |
HC002-0000027 | Male | 57.2 | 11.4 | 68.6 | Hispanic | Medicare | 29.4 | 88.3 | 173.3 | 75 | 0.917 | 24.3 | 0.7 | 8.1 | 5.5 | 1 | 0 | 137.1 | 226.3 | 13.5 | 4.57 | 51.5 | 3.08 | 32 | 187 | 105.3 | 42.7 | 195.3 | 144.3 | 5.8 | 4.12 | 104.4 | 90.3 | 138.1 | 3.2 | 12.5 | 2.49 | 151 | 89 | 1 | ACEi | Triple | 1 | 2,000 | 1.02 | 0 | null | 0 | 0 | 0 | 0 | 1 | Liraglutide_1.8mg | 1.41 | 5.2 | 0 | 0 | 1 | Sitagliptin_100mg | 0.88 | 0 | null | 0 | 0 | 1 | 0 | null | 0 | 0 | 0 | 0 | 89.5 | 9 | Western | 40.6 | 2,599 | 51.7 | 12.8 | 15.6 | Mixed | 3 | 50 | 6.5 | 30.7 | 8.2 | 8.3 | 18.1 | 1 | Former | 30 | 2 | 4.2 | 0 | 4.5 | 0.21 | Uncontrolled | 4.57 | null | 16.5 | 60.5 | 208 | 1 | 0 | 0 | 0 | 1 | Peripheral | 5 | 0 | 1 | 1 | 0 | 1 | 1 | 0 | 0 | 1 | 1 | Moderate | 0 | 1 | 0 | 0 | 2 | 0 | null | 1 | 0 | 4 | 0 | 0 | 1.87 | 9 | 4.1 | 7.9 | 0 | HC-END-002 | 42 | 2026-05-29T12:51:29Z |
HC002-0000028 | Male | 45.3 | 11.4 | 56.7 | Black | Private | 33.6 | 93.3 | 166.5 | 84.3 | 0.945 | 26.1 | 2.6 | 6.3 | 5.5 | 1 | 0 | 115.7 | 225.6 | 45.2 | 12.91 | 84 | 3.56 | 41.2 | 106.1 | 50 | 33.1 | 487.3 | 73 | 5.1 | 4.28 | 63.7 | 54.5 | 135.2 | 8.1 | 23.7 | 2.13 | 163 | 69 | 1 | Thiazide | Triple | 0 | 0 | 0 | 0 | null | 0 | 0 | 0 | 0 | 0 | null | 0 | 0 | 0 | 0 | 1 | Linagliptin_5mg | 0.67 | 0 | null | 0 | 0 | 0 | 0 | null | 0 | 0 | 0 | 0 | 69.8 | 7 | Low_carb | 40 | 2,776 | 19.4 | 13.2 | 12.9 | null | 0 | 0 | 7.9 | 30.6 | 4.6 | 5.6 | 7.2 | 0 | Never | 0 | 1 | 1.6 | 0 | 5.1 | -1.01 | Complication_burden | 12.91 | null | 19 | 79.8 | 85 | 1 | 0 | 0 | 0 | 0 | null | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 1 | Moderate | 1 | 11 | 0 | 0 | 3 | 0 | null | 1 | 1 | 2 | 1 | 0 | 2.39 | 7 | 7.3 | 7.7 | 0 | HC-END-002 | 42 | 2026-05-29T12:51:29Z |
HC002-0000029 | Male | 57.6 | 13.8 | 71.4 | Asian | Private | 25.4 | 72.1 | 168.3 | 75 | 0.819 | 22.4 | 3 | 8.1 | 5.5 | 1 | 0 | 129.4 | 212.3 | 107.5 | 25 | 30 | 0.77 | 15.8 | 186.1 | 62 | 42.1 | 409.7 | 143.9 | 4.9 | 4.24 | 31.9 | 20.5 | 72 | 8.5 | 13.9 | 2.27 | 140 | 88 | 1 | CCB | Triple | 1 | 2,000 | 0.99 | 0 | null | 0 | 0 | 0 | 0 | 1 | Liraglutide_1.8mg | 0.5 | 6.4 | 1 | 0 | 1 | Sitagliptin_100mg | 0.51 | 1 | Glipizide_5mg | 1 | 2.8 | 0 | 0 | null | 0 | 0 | 0 | 0 | 95.3 | 8 | Low_carb | 51.3 | 2,196 | 15.6 | 25.5 | 15.6 | Aerobic | 0 | 49 | 9.5 | 20.7 | 7 | 2.1 | 9.1 | 1 | Never | 0 | 3 | 5.3 | 0 | -1.1 | -1.42 | Insulin_requiring | 25 | Severe_NPDR | 13.2 | 63.4 | 169.6 | 1 | 0 | 0 | 0 | 0 | null | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 1 | High | 0 | 4 | 0 | 0 | 3 | 0 | null | 1 | 0 | 4 | 0 | 2 | 0.74 | 5.2 | 6.7 | 6.3 | 0 | HC-END-002 | 42 | 2026-05-29T12:51:29Z |
HC002-0000030 | Female | 33.3 | 30 | 63.3 | Other | Uninsured | 32.9 | 84.5 | 160.2 | 70.8 | 0.848 | 34.3 | 1.7 | 6.4 | 5.5 | 1 | 0 | 185.3 | 397.8 | 49.5 | 22.65 | 0 | 0.1 | 1.3 | 208.6 | 50 | 42.1 | 584.7 | 166.5 | 5.3 | 6.18 | 64.2 | 44.2 | 19.3 | 4.5 | 25.6 | 2.46 | 132 | 99 | 1 | ARB | Dual | 1 | 1,000 | 1.43 | 0 | null | 0 | 0 | 0 | 0 | 0 | null | 0 | 0 | 0 | 0 | 0 | null | 0 | 1 | Glipizide_10mg | 1 | 0.5 | 0 | 1 | Basal_only | 56.7 | 57.7 | 4.08 | 3.8 | 83.4 | 7 | Mediterranean | 80.9 | 1,842 | 38 | 26.8 | 7.1 | null | 0 | 0 | 6.7 | 24.5 | 8 | 5.6 | 10.5 | 0 | Former | 9 | 3 | 5.9 | 1 | 2 | -0.48 | Controlled | 22.65 | Severe_NPDR | 9.4 | 45.6 | 366.4 | 0 | 1 | 1 | 0 | 1 | Peripheral | 8 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | High | 0 | 4 | 0 | 0 | 1 | 0 | null | 0 | 1 | 1 | 1 | 0 | 1.84 | 6.1 | 6.4 | 8.6 | 0 | HC-END-002 | 42 | 2026-05-29T12:51:29Z |
HC002-0000031 | Female | 48.4 | 1 | 49.4 | Hispanic | Private | 35.4 | 88.2 | 157.9 | 75.8 | 0.827 | 39.7 | 2.6 | 5.5 | 5.5 | 1 | 0 | 76.8 | 154.5 | 57.9 | 10.98 | 155.3 | 6.98 | 81.3 | 179.9 | 85.5 | 56.9 | 187.2 | 123 | 4.7 | 10.3 | 125.9 | 88.9 | 30.7 | 6.4 | 31.8 | 2.26 | 153 | 96 | 1 | Thiazide | Monotherapy | 1 | 2,000 | 0.69 | 0 | null | 0 | 0 | 0 | 0 | 0 | null | 0 | 0 | 0 | 0 | 1 | Saxagliptin_5mg | 0.93 | 0 | null | 0 | 0 | 0 | 0 | null | 0 | 0 | 0 | 0 | 71.6 | 7 | Western | 66.5 | 2,246 | 40.5 | 23.7 | 15 | Mixed | 5 | 76 | 6.9 | 36.2 | 7.5 | 2.8 | 9.1 | 1 | Current | 10.1 | 2 | 1.6 | 0 | 2 | -0.09 | Controlled | 10.98 | null | 5.7 | 53.1 | 205.2 | 1 | 0 | 1 | 0 | 0 | null | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 1 | Moderate | 1 | 6 | 0 | 0 | 1 | 1 | Libre3 | 1 | 0 | 6 | 2 | 2 | 3.44 | 8.3 | 5.9 | 8.7 | 0 | HC-END-002 | 42 | 2026-05-29T12:51:29Z |
HC002-0000032 | Female | 53.2 | 7.3 | 60.5 | Asian | Medicare | 36.5 | 100.1 | 165.6 | 81.6 | 0.907 | 41.5 | 4.2 | 6.7 | 5.5 | 1 | 0 | 108 | 143 | 32.1 | 8.55 | 86.7 | 4.21 | 52.7 | 178.1 | 68.1 | 33.8 | 381.1 | 144.4 | 7 | 8.95 | 73 | 37.6 | 42.7 | 5.9 | 41.3 | 3.14 | 136 | 92 | 1 | Beta_blocker | Triple | 1 | 2,000 | 1.18 | 1 | Empagliflozin_10mg | 0.63 | 0.8 | 3.5 | 0 | 0 | null | 0 | 0 | 0 | 0 | 0 | null | 0 | 0 | null | 0 | 0 | 0 | 0 | null | 0 | 0 | 0 | 0 | 51.7 | 5 | Western | 39.4 | 2,149 | 54.7 | 8 | 15 | Aerobic | 5 | 42 | 5.2 | 29.1 | 4.3 | 2.7 | 28.3 | 1 | Never | 0 | 2 | 5.6 | 1 | 0.3 | -0.68 | Insulin_requiring | 8.55 | Mild_NPDR | 6.9 | 65.8 | 43.3 | 1 | 0 | 0 | 0 | 0 | null | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 1 | High | 0 | 5 | 0 | 0 | 4 | 0 | null | 1 | 0 | 5 | 2 | 2 | 4.71 | 4.6 | 10 | 6.1 | 0 | HC-END-002 | 42 | 2026-05-29T12:51:29Z |
HC002-0000033 | Male | 51 | 3.5 | 54.5 | Other | Private | 32.2 | 98.4 | 174.7 | 75 | 0.981 | 25.7 | 4.1 | 10.8 | 10.2 | 0 | 1 | 177.7 | 361.9 | 33.3 | 14.62 | 139.7 | 6.37 | 70.6 | 148.4 | 50 | 24 | 413.7 | 124.3 | 6 | 3.64 | 33.9 | 17.1 | 54.8 | 14.5 | 31.3 | 2.17 | 135 | 89 | 1 | ACEi | Dual | 0 | 0 | 0 | 0 | null | 0 | 0 | 0 | 0 | 1 | Semaglutide_0.5mg | 1.17 | 4.7 | 0 | 0 | 0 | null | 0 | 0 | null | 0 | 0 | 0 | 0 | null | 0 | 0 | 0 | 0 | 82.2 | 6 | Mixed | 41.7 | 2,647 | 39.6 | 8 | 10.5 | Aerobic | 6 | 33 | 4 | 35.4 | 5.2 | 0.8 | 3.9 | 0 | Never | 0 | 3 | 0.4 | 0 | 1.5 | 0.38 | Controlled | 14.62 | null | 5.1 | 95 | 90.7 | 1 | 0 | 0 | 0 | 1 | Autonomic | 5 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 1 | Moderate | 0 | 2 | 0 | 0 | 2 | 1 | Libre3 | 1 | 0 | 6 | 3 | 2 | 2.86 | 7 | 5.4 | 5.2 | 0 | HC-END-002 | 42 | 2026-05-29T12:51:29Z |
HC002-0000034 | Male | 61.5 | 17.7 | 79.2 | Asian | Medicare | 31.8 | 105.3 | 182 | 75 | 0.924 | 28.6 | 2 | 8 | 8.7 | 0 | 0 | 207.1 | 413.2 | 65.1 | 25 | 18.2 | 0.87 | 10.6 | 146.9 | 63.4 | 23.6 | 299.8 | 123.4 | 6.3 | 14.81 | 200 | 142.6 | 28.5 | 4.7 | 42.4 | 4.82 | 149 | 65 | 1 | CCB | Dual | 0 | 0 | 0 | 0 | null | 0 | 0 | 0 | 0 | 0 | null | 0 | 0 | 0 | 0 | 0 | null | 0 | 0 | null | 0 | 0 | 0 | 0 | null | 0 | 0 | 0 | 0 | 83.6 | 4 | DASH | 69.6 | 1,494 | 53.2 | 18.7 | 9.3 | Mixed | 4 | 36 | 5.6 | 27.2 | 6.7 | 2 | 34.5 | 1 | Former | 25.6 | 4 | 8.6 | 0 | 1.4 | 0.71 | Complication_burden | 25 | null | 3.6 | 84.5 | 729.4 | 0 | 1 | 0 | 0 | 1 | Autonomic | 4 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | Moderate | 0 | 2 | 0 | 0 | 3 | 0 | null | 0 | 0 | 2 | 0 | 1 | 2.1 | 4.5 | 3.1 | 7.4 | 1 | HC-END-002 | 42 | 2026-05-29T12:51:29Z |
HC002-0000035 | Male | 56.1 | 30 | 86.1 | Hispanic | Uninsured | 35.3 | 117.7 | 182.6 | 76.6 | 0.995 | 35.6 | 1.1 | 8.8 | 5.5 | 1 | 0 | 124.2 | 219.2 | 119.7 | 25 | 14.8 | 0.1 | 0 | 254.8 | 141.7 | 20 | 465.6 | 234.8 | 4.5 | 12.76 | 44.4 | 29.1 | 54.6 | 7.7 | 36.6 | 2.24 | 151 | 88 | 1 | Combination | Dual | 1 | 500 | 0.98 | 0 | null | 0 | 0 | 0 | 0 | 0 | null | 0 | 0 | 0 | 0 | 0 | null | 0 | 0 | null | 0 | 0 | 1 | 1 | Basal_only | 21.7 | 21.8 | 1.78 | 4.8 | 87 | 9 | Mediterranean | 61.3 | 2,394 | 33.2 | 24.7 | 8.6 | null | 0 | 7 | 11.5 | 18.4 | 7.4 | 3.4 | 33.2 | 1 | Never | 0 | 6 | 6.5 | 0 | 3.2 | -1.56 | Complication_burden | 25 | PDR | 19.7 | 40.9 | 750.4 | 0 | 1 | 1 | 0 | 1 | Peripheral | 2 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | null | 0 | 6 | 0 | 1 | 1 | 0 | null | 1 | 1 | 3 | 2 | 0 | 3.68 | 5.6 | 5.2 | 7.2 | 0 | HC-END-002 | 42 | 2026-05-29T12:51:29Z |
HC002-0000036 | Male | 60 | 4.8 | 64.9 | White | Medicare | 24.2 | 72.8 | 173.4 | 75 | 1.003 | 19.5 | 2.6 | 7.6 | 6.9 | 1 | 0 | 147.3 | 257.3 | 77.3 | 25 | 139.3 | 6.07 | 68.8 | 256.2 | 79.6 | 20 | 783.1 | 236.2 | 5.8 | 3.44 | 67.8 | 52.1 | 157 | 5.4 | 32.7 | 1.02 | 164 | 71 | 1 | ARB | Monotherapy | 0 | 0 | 0 | 0 | null | 0 | 0 | 0 | 0 | 0 | null | 0 | 0 | 0 | 0 | 0 | null | 0 | 0 | null | 0 | 0 | 1 | 0 | null | 0 | 0 | 0 | 0 | 76.7 | 6 | Mixed | 65 | 2,205 | 47.3 | 28.5 | 8.6 | HIIT | 3 | 19 | 7.8 | 28.1 | 7.4 | 3.9 | 12.5 | 1 | Former | 60 | 3 | 3.9 | 0 | -0.7 | -0.63 | Controlled | 25 | null | 6.4 | 88.2 | 115.3 | 1 | 0 | 0 | 0 | 1 | Peripheral | 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | High | 0 | 5 | 0 | 0 | 1 | 0 | null | 1 | 0 | 6 | 2 | 0 | 4.45 | 5.3 | 5.4 | 3.4 | 1 | HC-END-002 | 42 | 2026-05-29T12:51:29Z |
HC002-0000037 | Male | 43.7 | 9 | 52.7 | White | Uninsured | 27.7 | 88.8 | 179.2 | 75 | 0.914 | 20.4 | 3.2 | 5.5 | 5.5 | 1 | 0 | 104.2 | 213.8 | 55.8 | 14.35 | 80.6 | 3.85 | 46.9 | 184.9 | 111.2 | 33.4 | 201.6 | 151.5 | 6.4 | 13.17 | 39.2 | 15.7 | 72.7 | 6.3 | 13.3 | 2.93 | 144 | 99 | 1 | Beta_blocker | Dual | 1 | 2,000 | 1.14 | 0 | null | 0 | 0 | 0 | 0 | 0 | null | 0 | 0 | 0 | 0 | 0 | null | 0 | 0 | null | 0 | 0 | 0 | 1 | Basal_only | 29.9 | 35.5 | 3.67 | 3.6 | 97.1 | 8 | Mediterranean | 72.6 | 1,915 | 34.3 | 18 | 9.5 | Aerobic | 4 | 33 | 4 | 36.7 | 6.8 | 4.5 | 30.6 | 1 | Never | 0 | 6 | 5.8 | 0 | 4.8 | -1.77 | Uncontrolled | 14.35 | Moderate_NPDR | 6.2 | 96.1 | 136.7 | 1 | 0 | 0 | 0 | 1 | Autonomic | 8 | 1 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | null | 0 | 3 | 0 | 0 | 6 | 0 | null | 0 | 0 | 6 | 0 | 1 | 4.37 | 7 | 3.7 | 7.3 | 0 | HC-END-002 | 42 | 2026-05-29T12:51:29Z |
HC002-0000038 | Male | 62.8 | 0.7 | 63.5 | Hispanic | Private | 34.2 | 102.9 | 173.3 | 76 | 0.93 | 31.5 | 0.4 | 9.9 | 8.3 | 0 | 0 | 189.2 | 318.3 | 39.9 | 18.63 | 127.3 | 6.34 | 75.5 | 195.7 | 109.5 | 34.3 | 259.1 | 161.3 | 5.8 | 8.65 | 44.6 | 25.9 | 71.2 | 7.7 | 23.3 | 2.62 | 166 | 96 | 1 | CCB | Monotherapy | 1 | 1,000 | 0.55 | 1 | Empagliflozin_10mg | 0.64 | 1.4 | 1.7 | 0 | 0 | null | 0 | 0 | 0 | 0 | 1 | Sitagliptin_100mg | 0.56 | 1 | Glipizide_5mg | 1 | 2.1 | 0 | 0 | null | 0 | 0 | 0 | 0 | 91.3 | 10 | Western | 47.6 | 1,999 | 49.2 | 11.3 | 13 | Mixed | 2 | 36 | 6.7 | 24.7 | 7.7 | 3.3 | 10.4 | 1 | Current | 3 | 1 | 6 | 1 | -3.1 | -0 | Uncontrolled | 18.63 | null | 1.5 | 60.3 | 132 | 1 | 0 | 0 | 0 | 0 | null | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | null | 0 | 5 | 0 | 0 | 3 | 0 | null | 1 | 0 | 4 | 1 | 0 | 3.52 | 7.3 | 6.1 | 5.1 | 0 | HC-END-002 | 42 | 2026-05-29T12:51:29Z |
HC002-0000039 | Male | 71.5 | 9.1 | 80.6 | Hispanic | Medicare | 45.4 | 154 | 184.3 | 109.9 | 0.826 | 44.3 | 4.7 | 5.5 | 5.5 | 1 | 0 | 123.7 | 178.5 | 50.2 | 15.31 | 70.8 | 3.64 | 40.4 | 147.7 | 50 | 33.7 | 358.3 | 114 | 5.6 | 7.69 | 61.9 | 43.5 | 38.7 | 4.8 | 36.3 | 2.23 | 156 | 72 | 1 | ARB | Monotherapy | 1 | 2,000 | 1.53 | 1 | Canagliflozin_300mg | 1.09 | 0.5 | 6 | 0 | 0 | null | 0 | 0 | 0 | 0 | 0 | null | 0 | 0 | null | 0 | 0 | 0 | 0 | null | 0 | 0 | 0 | 0 | 95.6 | 5 | Low_carb | 60.2 | 2,933 | 25.9 | 19.4 | 11.4 | Aerobic | 2 | 50 | 9.8 | 28.5 | 7.3 | 4.9 | 14.4 | 0 | Never | 0 | 2 | 6.5 | 0 | 6.1 | -0.81 | Controlled | 15.31 | null | 2.9 | 74.4 | 218 | 1 | 0 | 0 | 0 | 1 | Peripheral | 4 | 1 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | null | 0 | 4 | 0 | 0 | 2 | 0 | null | 0 | 0 | 8 | 3 | 1 | 1.74 | 10 | 10 | 2.8 | 0 | HC-END-002 | 42 | 2026-05-29T12:51:29Z |
HC002-0000040 | Female | 40.4 | 5.3 | 45.6 | White | Medicaid | 25.9 | 69.5 | 163.6 | 65 | 0.795 | 32.6 | 0.4 | 7.5 | 6.1 | 1 | 0 | 168.3 | 266.2 | 23.1 | 9.6 | 105.3 | 4.6 | 60.6 | 209.4 | 50 | 43 | 741.8 | 166.4 | 5.5 | 7.58 | 81.2 | 52.7 | 20.9 | 8.1 | 27.4 | 1.96 | 143 | 83 | 1 | Combination | Dual | 1 | 1,500 | 1.06 | 0 | null | 0 | 0 | 0 | 0 | 0 | null | 0 | 0 | 0 | 0 | 0 | null | 0 | 1 | Glipizide_10mg | 2 | 2.5 | 0 | 0 | null | 0 | 0 | 0 | 0 | 72.2 | 7 | Mediterranean | 85.7 | 1,356 | 42.3 | 23.7 | 7.5 | Mixed | 3 | 63 | 6.9 | 28.6 | 6.6 | 6 | 23.8 | 1 | Never | 0 | 3 | 5.6 | 1 | -6.5 | -0.69 | Uncontrolled | 9.6 | null | 12.8 | 78.6 | 304.4 | 0 | 1 | 0 | 0 | 0 | null | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | Moderate | 0 | 1 | 0 | 0 | 2 | 0 | null | 0 | 1 | 7 | 1 | 1 | 2.72 | 5.9 | 3.7 | 7.6 | 0 | HC-END-002 | 42 | 2026-05-29T12:51:29Z |
HC002-0000041 | Male | 41.3 | 13.9 | 55.2 | Hispanic | Medicare | 31.5 | 87.4 | 166.7 | 76.3 | 0.915 | 29 | 2.3 | 8.3 | 6.1 | 1 | 0 | 138 | 212.3 | 17 | 5.79 | 59.5 | 1.88 | 23.6 | 251.9 | 176.1 | 42.2 | 167.7 | 209.7 | 8 | 6.67 | 110.2 | 72.5 | 28.8 | 8.3 | 49.6 | 0.85 | 153 | 88 | 1 | CCB | Triple | 1 | 2,000 | 0.87 | 0 | null | 0 | 0 | 0 | 0 | 0 | null | 0 | 0 | 0 | 0 | 0 | null | 0 | 0 | null | 0 | 0 | 0 | 1 | Basal_bolus | 41.3 | 82.8 | 2.04 | 3.9 | 85.1 | 7 | Mediterranean | 52.5 | 2,133 | 43.1 | 14.3 | 9.5 | Mixed | 3 | 41 | 8.5 | 35.1 | 7.4 | 5.1 | 16.8 | 1 | Never | 0 | 1 | 7.4 | 1 | -8.1 | 0.29 | Complication_burden | 5.79 | Severe_NPDR | 11.4 | 82.8 | 391.2 | 0 | 1 | 0 | 0 | 1 | Peripheral | 5 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | null | 1 | 13 | 0 | 0 | 1 | 0 | null | 1 | 0 | 5 | 2 | 1 | 3.14 | 6.8 | 3.5 | 4.3 | 0 | HC-END-002 | 42 | 2026-05-29T12:51:29Z |
HC002-0000042 | Female | 68 | 9.6 | 77.6 | Hispanic | Private | 36.7 | 106.9 | 170.6 | 81.5 | 0.864 | 41.9 | 2 | 8.8 | 5.5 | 1 | 0 | 163.4 | 312.7 | 21.7 | 8.77 | 95.1 | 4.42 | 50.1 | 126.9 | 50 | 52.1 | 339.3 | 74.8 | 5.3 | 10.27 | 53.2 | 35.6 | 23.5 | 5.3 | 40 | 0.92 | 127 | 95 | 1 | Combination | Insulin_based | 1 | 1,000 | 1.56 | 1 | Dapagliflozin_10mg | 1.37 | 3.1 | 2.7 | 0 | 0 | null | 0 | 0 | 0 | 0 | 1 | Linagliptin_5mg | 0.63 | 0 | null | 0 | 0 | 0 | 0 | null | 0 | 0 | 0 | 0 | 79.3 | 7 | Low_carb | 62.3 | 1,685 | 28.6 | 20.3 | 14.2 | Aerobic | 4 | 49 | 6.2 | 22 | 6 | 3.9 | 14.3 | 1 | Never | 0 | 4 | 3 | 1 | -2.8 | -1.2 | Insulin_requiring | 8.77 | null | 9.9 | 57.5 | 44 | 1 | 0 | 1 | 0 | 1 | Autonomic | 4 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 1 | High | 0 | 2 | 0 | 0 | 0 | 0 | null | 0 | 1 | 3 | 2 | 1 | 0 | 8.6 | 8.1 | 9.5 | 0 | HC-END-002 | 42 | 2026-05-29T12:51:29Z |
HC002-0000043 | Female | 49.7 | 23.1 | 72.8 | Asian | Medicaid | 36.5 | 93.7 | 160.2 | 75.6 | 0.803 | 43.3 | 3.6 | 7.2 | 5.5 | 1 | 0 | 93.1 | 136.1 | 41.4 | 9.52 | 51.4 | 1.95 | 23.1 | 202.6 | 98.4 | 40.6 | 317.9 | 162 | 6.5 | 8.26 | 39.4 | 26.8 | 67.2 | 9.3 | 35.8 | 4.62 | 161 | 67 | 1 | Thiazide | Triple | 1 | 1,000 | 0.69 | 0 | null | 0 | 0 | 0 | 0 | 0 | null | 0 | 0 | 0 | 0 | 0 | null | 0 | 0 | null | 0 | 0 | 0 | 1 | Basal_only | 34.5 | 72.2 | 1.59 | 3.8 | 65 | 5 | Mediterranean | 78.5 | 2,070 | 43.2 | 33.3 | 7.7 | Resistance | 4 | 14 | 7.4 | 27.1 | 7.6 | 5.3 | 19.4 | 1 | Former | 17 | 2 | 5.2 | 0 | -3 | -1.35 | Insulin_requiring | 9.52 | DME | 3 | 56.8 | 67.8 | 1 | 0 | 1 | 0 | 0 | null | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | null | 1 | 14 | 0 | 0 | 5 | 1 | Libre3 | 0 | 1 | 6 | 2 | 0 | 2.84 | 6.1 | 6.1 | 8.4 | 0 | HC-END-002 | 42 | 2026-05-29T12:51:29Z |
HC002-0000044 | Male | 68.8 | 7.9 | 76.8 | White | Private | 31 | 93.6 | 173.7 | 75.2 | 0.929 | 25.2 | 0.1 | 5.5 | 5.5 | 1 | 0 | 100.8 | 189.5 | 31.9 | 7.95 | 98 | 4.84 | 52.8 | 205.5 | 122.2 | 43.6 | 198.8 | 161.9 | 6.9 | 5.49 | 76.4 | 64.6 | 75.3 | 6.5 | 70 | 1.69 | 163 | 57 | 1 | Beta_blocker | Dual | 1 | 2,000 | 0.8 | 0 | null | 0 | 0 | 0 | 0 | 0 | null | 0 | 0 | 0 | 0 | 1 | Alogliptin_25mg | 0.46 | 1 | Glimepiride_4mg | 1 | 2.3 | 0 | 1 | Premixed | 25.9 | 52.3 | 2.09 | 2.3 | 63.2 | 8 | Western | 31.8 | 2,018 | 46.9 | 14.3 | 13.6 | HIIT | 1 | 28 | 8.6 | 25.5 | 5.8 | 1.7 | 41.6 | 1 | Former | 8.4 | 9 | 9.1 | 0 | 5.8 | -1.77 | Complication_burden | 7.95 | null | 12.4 | 64.4 | 75.8 | 1 | 0 | 0 | 0 | 0 | null | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 1 | 1 | High | 1 | 12 | 0 | 0 | 2 | 0 | null | 0 | 0 | 3 | 3 | 0 | 5.21 | 6.4 | 5.7 | 7.3 | 0 | HC-END-002 | 42 | 2026-05-29T12:51:29Z |
HC002-0000045 | Female | 46.7 | 9.1 | 55.8 | White | Medicare | 34.1 | 92.5 | 164.8 | 76.2 | 0.786 | 38.2 | 0.3 | 7.1 | 6.6 | 1 | 0 | 111.1 | 191 | 17.4 | 4.77 | 79.7 | 3.09 | 42.7 | 205 | 108.8 | 50.7 | 227.5 | 154.3 | 6.4 | 2.1 | 75 | 52.8 | 34.9 | 6.6 | 24.2 | 3.4 | 167 | 84 | 1 | Beta_blocker | Triple | 1 | 2,000 | 0.37 | 0 | null | 0 | 0 | 0 | 0 | 1 | Dulaglutide_1.5mg | 0.99 | 4.2 | 0 | 0 | 0 | null | 0 | 0 | null | 0 | 0 | 0 | 0 | null | 0 | 0 | 0 | 0 | 64.6 | 5 | Western | 39.3 | 2,022 | 53.2 | 18.7 | 9.9 | Mixed | 0 | 56 | 7.7 | 25.1 | 7.4 | 6.1 | 42.9 | 1 | Current | 13.7 | 2 | 4.8 | 0 | 3.6 | 0.36 | Complication_burden | 4.77 | null | 5.1 | 74.7 | 26.6 | 0 | 0 | 0 | 0 | 0 | null | 0 | 1 | 0 | 0 | 1 | 0 | 1 | 0 | 0 | 1 | 1 | Moderate | 0 | 1 | 0 | 0 | 2 | 0 | null | 1 | 0 | 4 | 2 | 0 | 1.9 | 7.4 | 8.9 | 9.7 | 0 | HC-END-002 | 42 | 2026-05-29T12:51:29Z |
HC002-0000046 | Female | 69.5 | 26.7 | 90 | Asian | Uninsured | 36.7 | 90.5 | 157 | 78.4 | 0.87 | 40.3 | 2.3 | 7.2 | 5.5 | 1 | 0 | 125.4 | 257.7 | 39.5 | 12.24 | 0 | 0.1 | 0 | 247.4 | 153.5 | 41 | 264.5 | 206.4 | 4.4 | 10.16 | 77.5 | 57.4 | 70.4 | 7.5 | 81.6 | 1.07 | 132 | 57 | 1 | Combination | Dual | 1 | 1,500 | 1.62 | 1 | Dapagliflozin_10mg | 0.79 | 3.2 | 6.1 | 0 | 0 | null | 0 | 0 | 0 | 0 | 0 | null | 0 | 1 | Glipizide_5mg | 4 | 2 | 0 | 1 | Basal_bolus | 34.9 | 71.9 | 2.64 | 2.7 | 86.9 | 10 | Vegan | 79.1 | 1,772 | 53.3 | 15.2 | 4.6 | HIIT | 5 | 32 | 7.6 | 26.7 | 7.4 | 2.9 | 26.9 | 1 | Former | 6.7 | 1 | 6 | 0 | 0.1 | 0.22 | Complication_burden | 12.24 | DME | 12.7 | 73.1 | 801.7 | 0 | 1 | 0 | 0 | 1 | Both | 5 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 1 | Moderate | 1 | 18 | 0 | 0 | 1 | 0 | null | 1 | 0 | 3 | 2 | 1 | 0.26 | 4.8 | 5.3 | 8.8 | 0 | HC-END-002 | 42 | 2026-05-29T12:51:29Z |
HC002-0000047 | Male | 53.6 | 8.3 | 61.8 | Asian | Private | 37.7 | 106.2 | 167.7 | 90.5 | 0.986 | 36.1 | 3.8 | 7.2 | 5.5 | 1 | 0 | 95.2 | 165.3 | 34.3 | 8.06 | 86 | 3.61 | 40.6 | 262.4 | 181.9 | 36 | 222.1 | 226.4 | 6 | 6.02 | 73.8 | 65.1 | 157.4 | 6.9 | 29.1 | 1.37 | 122 | 86 | 1 | Thiazide | Dual | 1 | 1,500 | 1.85 | 1 | Canagliflozin_300mg | 1.2 | 3.9 | 5.4 | 0 | 0 | null | 0 | 0 | 0 | 0 | 0 | null | 0 | 0 | null | 0 | 0 | 0 | 0 | null | 0 | 0 | 0 | 0 | 61.4 | 5 | Mediterranean | 84.6 | 2,168 | 42.9 | 28.5 | 6.1 | Resistance | 2 | 50 | 11.1 | 25.2 | 6.4 | 6.5 | 17.1 | 1 | Never | 0 | 4 | 3.5 | 1 | -6 | -0.58 | Controlled | 8.06 | null | 10.7 | 101.3 | 36.4 | 1 | 0 | 0 | 0 | 0 | null | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 1 | High | 0 | 1 | 0 | 0 | 2 | 0 | null | 1 | 0 | 6 | 2 | 2 | 1.87 | 6.6 | 3.1 | 4.9 | 0 | HC-END-002 | 42 | 2026-05-29T12:51:29Z |
HC002-0000048 | Male | 55.1 | 14.1 | 69.2 | Other | Private | 30.4 | 96.8 | 178.6 | 75 | 0.984 | 23.2 | 0.3 | 10 | 8.5 | 0 | 0 | 192.7 | 411.7 | 19.5 | 9.28 | 71.5 | 3.28 | 36.3 | 176.1 | 101.2 | 48.5 | 132.2 | 127.7 | 6 | 10.59 | 58 | 45.7 | 191.9 | 9.6 | 16.7 | 2.99 | 140 | 92 | 1 | Combination | Monotherapy | 1 | 1,500 | 0.43 | 0 | null | 0 | 0 | 0 | 0 | 0 | null | 0 | 0 | 0 | 0 | 0 | null | 0 | 0 | null | 0 | 0 | 0 | 0 | null | 0 | 0 | 0 | 0 | 69.3 | 4 | Vegan | 82.5 | 1,842 | 55.6 | 19.8 | 6.6 | Aerobic | 2 | 23 | 8.8 | 23.5 | 7.6 | 5.9 | 25.5 | 1 | Current | 24.8 | 0 | 9.8 | 1 | 5.6 | -1.17 | Uncontrolled | 9.28 | Mild_NPDR | 4.3 | 87.2 | 134.5 | 1 | 0 | 0 | 0 | 0 | null | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 1 | 1 | High | 0 | 2 | 0 | 0 | 2 | 0 | null | 1 | 0 | 5 | 1 | 1 | 1.82 | 4.6 | 8.3 | 8.9 | 0 | HC-END-002 | 42 | 2026-05-29T12:51:29Z |
HC002-0000049 | Female | 70.8 | 3.6 | 74.4 | Asian | Private | 43.3 | 115.8 | 163.5 | 91.4 | 0.861 | 49.1 | 3.2 | 6.5 | 5.5 | 1 | 0 | 85.7 | 180.8 | 35.6 | 7.53 | 106.9 | 5 | 60.7 | 210.6 | 127.1 | 33.4 | 250.2 | 177.2 | 5.8 | 10.94 | 70.4 | 60.8 | 110.6 | 6.3 | 81.4 | 2.1 | 174 | 98 | 1 | ACEi | Monotherapy | 1 | 2,000 | 0.77 | 0 | null | 0 | 0 | 0 | 0 | 0 | null | 0 | 0 | 0 | 0 | 1 | Linagliptin_5mg | 0.67 | 0 | null | 0 | 0 | 0 | 0 | null | 0 | 0 | 0 | 0 | 88.4 | 5 | DASH | 72.7 | 1,560 | 45.1 | 27.5 | 6.8 | Mixed | 7 | 43 | 5.7 | 31.8 | 8.7 | 6.2 | 13.8 | 0 | Never | 0 | 4 | 6.1 | 1 | -7.7 | 0.1 | Uncontrolled | 7.53 | null | 10.7 | 54.7 | 40.6 | 1 | 0 | 1 | 0 | 0 | null | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | null | 1 | 9 | 0 | 0 | 3 | 0 | null | 1 | 1 | 5 | 1 | 0 | 4.34 | 5.6 | 6.4 | 5.4 | 0 | HC-END-002 | 42 | 2026-05-29T12:51:29Z |
HC002-0000050 | Male | 47.7 | 20.3 | 68 | Asian | Private | 22.4 | 65.1 | 170.6 | 75 | 0.868 | 18.4 | 1.9 | 8.9 | 5.5 | 1 | 0 | 164.2 | 240.8 | 27.8 | 11.28 | 35.4 | 1.1 | 11.8 | 188.2 | 61.2 | 34.3 | 463.3 | 153.9 | 7.2 | 4.61 | 53.8 | 34.1 | 47.6 | 10.4 | 10.5 | 2.8 | 154 | 79 | 1 | CCB | Triple | 1 | 2,000 | 1.13 | 1 | Empagliflozin_10mg | 0.76 | 1.7 | 2.3 | 0 | 0 | null | 0 | 0 | 0 | 0 | 0 | null | 0 | 1 | Glipizide_10mg | 2 | 2.9 | 0 | 1 | Basal_only | 43.6 | 63.8 | 3.5 | 2.4 | 94.6 | 7 | Western | 45.6 | 2,160 | 51.5 | 18.4 | 12.2 | Resistance | 5 | 45 | 4.8 | 43.5 | 5.6 | 4.7 | 31.9 | 1 | Former | 20.2 | 2 | 3 | 0 | -0.4 | 1.25 | Uncontrolled | 11.28 | Severe_NPDR | 20.1 | 47 | 63.6 | 1 | 0 | 1 | 0 | 1 | Both | 3 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | Low | 1 | 15 | 0 | 0 | 3 | 0 | null | 1 | 0 | 2 | 0 | 2 | 6 | 10 | 6.2 | 8.7 | 1 | HC-END-002 | 42 | 2026-05-29T12:51:29Z |
HC002-0000051 | Male | 40.7 | 14.8 | 55.5 | White | Private | 37.1 | 123.7 | 182.5 | 85 | 0.923 | 34.6 | 2.9 | 8.7 | 7.7 | 0 | 0 | 124.9 | 239.5 | 28.9 | 8.91 | 54.5 | 2.71 | 29.9 | 161 | 64.9 | 40 | 280.8 | 121 | 6.4 | 13.77 | 110.9 | 71.5 | 100.7 | 5.6 | 21.7 | 2.19 | 138 | 87 | 1 | CCB | Dual | 1 | 2,000 | 0.89 | 0 | null | 0 | 0 | 0 | 0 | 0 | null | 0 | 0 | 0 | 0 | 0 | null | 0 | 0 | null | 0 | 0 | 0 | 0 | null | 0 | 0 | 0 | 0 | 51.7 | 4 | Mediterranean | 55.8 | 2,451 | 41.8 | 18.3 | 8.3 | null | 0 | 4 | 10.9 | 18.3 | 7.9 | 5 | 37.1 | 1 | Former | 25.7 | 11 | 7.7 | 1 | -4.3 | -0.54 | Insulin_requiring | 8.91 | Mild_NPDR | 9.8 | 82.7 | 449.6 | 0 | 1 | 0 | 0 | 0 | null | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 0 | null | 0 | 3 | 1 | 0 | 3 | 0 | null | 1 | 0 | 2 | 1 | 0 | 3.02 | 5.9 | 2.2 | 5.9 | 0 | HC-END-002 | 42 | 2026-05-29T12:51:29Z |
HC002-0000052 | Male | 46.6 | 15.3 | 62 | White | Medicare | 29 | 91.3 | 177.5 | 75 | 0.936 | 23 | 2.7 | 9.9 | 6 | 1 | 0 | 153.5 | 229.2 | 60.8 | 23.03 | 57.9 | 2.45 | 32.4 | 195.3 | 50 | 21.2 | 792.9 | 174.1 | 7.3 | 7.33 | 200 | 150 | 130.9 | 5 | 22.5 | 2 | 124 | 93 | 1 | ACEi | Triple | 1 | 2,000 | 1.09 | 0 | null | 0 | 0 | 0 | 0 | 1 | Liraglutide_1.2mg | 2.03 | 5.1 | 1 | 0 | 0 | null | 0 | 1 | Glyburide_5mg | 1 | 2 | 0 | 0 | null | 0 | 0 | 0 | 0 | 90.3 | 8 | Mediterranean | 63 | 2,569 | 34 | 15 | 7.9 | null | 0 | 5 | 8 | 20.6 | 8.1 | 3.9 | 57.8 | 1 | Never | 0 | 5 | 3.4 | 0 | 3.2 | -1.12 | Complication_burden | 23.03 | Severe_NPDR | 8.9 | 76.9 | 139.8 | 1 | 0 | 0 | 0 | 0 | null | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | null | 1 | 9 | 0 | 0 | 0 | 0 | null | 0 | 0 | 2 | 1 | 0 | 1.61 | 6.6 | 4.3 | 4.2 | 0 | HC-END-002 | 42 | 2026-05-29T12:51:29Z |
HC002-0000053 | Female | 57.4 | 16.1 | 73.6 | White | Private | 27.4 | 71.4 | 161.3 | 65 | 0.836 | 26.1 | 0.5 | 8.2 | 8.5 | 0 | 0 | 181.4 | 370.3 | 12.5 | 5.62 | 18.8 | 1.61 | 21.8 | 210.5 | 117.3 | 35 | 291.2 | 175.5 | 4.4 | 6.94 | 60.4 | 49.7 | 17.1 | 4.5 | 66.4 | 1.62 | 137 | 71 | 1 | Combination | Triple | 0 | 0 | 0 | 0 | null | 0 | 0 | 0 | 0 | 0 | null | 0 | 0 | 0 | 0 | 0 | null | 0 | 0 | null | 0 | 0 | 0 | 0 | null | 0 | 0 | 0 | 0 | 81.4 | 3 | Low_carb | 45.4 | 1,200 | 17.1 | 11 | 6.9 | null | 0 | 2 | 10.1 | 17.4 | 6.6 | 2.9 | 10.9 | 0 | Former | 10.1 | 3 | 6.9 | 0 | -0.1 | 0.35 | Complication_burden | 5.62 | Moderate_NPDR | 6.3 | 58.3 | 808.5 | 0 | 1 | 1 | 0 | 0 | null | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | null | 0 | 2 | 0 | 0 | 4 | 1 | Libre2 | 0 | 0 | 3 | 1 | 1 | 1.11 | 0.9 | 6.1 | 7.7 | 0 | HC-END-002 | 42 | 2026-05-29T12:51:29Z |
HC002-0000054 | Female | 33.2 | 13.5 | 46.7 | Hispanic | Medicare | 22.1 | 64.5 | 171.1 | 65 | 0.864 | 19.5 | 3.7 | 9.7 | 5.6 | 1 | 0 | 193.4 | 362.1 | 11.1 | 5.29 | 59.4 | 2.44 | 28.6 | 193.2 | 101.1 | 49.4 | 213.6 | 143.8 | 6.2 | 5.2 | 51.4 | 38 | 128.1 | 4.5 | 15 | 1.29 | 133 | 96 | 1 | Beta_blocker | Monotherapy | 0 | 0 | 0 | 0 | null | 0 | 0 | 0 | 0 | 1 | Dulaglutide_1.5mg | 1.79 | 6.5 | 0 | 0 | 0 | null | 0 | 0 | null | 0 | 0 | 0 | 1 | Basal_bolus | 28.5 | 60.5 | 2.12 | 1.6 | 75.2 | 7 | Mediterranean | 78.6 | 1,968 | 42.9 | 20.8 | 10.2 | Resistance | 2 | 29 | 9.5 | 34.1 | 7.8 | 7.5 | 9 | 0 | Current | 8.3 | 3 | 7.6 | 0 | 5.8 | -1.08 | Uncontrolled | 5.29 | null | 14 | 50.3 | 472.5 | 0 | 1 | 1 | 0 | 1 | Autonomic | 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | null | 0 | 1 | 0 | 0 | 5 | 0 | null | 1 | 0 | 6 | 1 | 2 | 4.24 | 7.1 | 4.2 | 5.8 | 0 | HC-END-002 | 42 | 2026-05-29T12:51:29Z |
HC002-0000055 | Female | 59.6 | 1.2 | 60.8 | Other | Private | 34.1 | 95.9 | 167.8 | 73.4 | 0.946 | 36.2 | 3.1 | 8.1 | 7 | 1 | 0 | 179.8 | 281.4 | 39.1 | 17.36 | 141.4 | 6.44 | 74 | 151.5 | 59.9 | 31.3 | 301.9 | 120.2 | 6.3 | 19.46 | 83.3 | 57.1 | 44.9 | 13.9 | 19.7 | 4.14 | 163 | 86 | 1 | Beta_blocker | Monotherapy | 1 | 2,000 | 0.72 | 0 | null | 0 | 0 | 0 | 0 | 0 | null | 0 | 0 | 0 | 0 | 0 | null | 0 | 1 | Glimepiride_4mg | 0 | 2.8 | 0 | 0 | null | 0 | 0 | 0 | 0 | 72.9 | 6 | DASH | 73 | 2,141 | 48.7 | 23.9 | 9 | Mixed | 7 | 42 | 7.5 | 31.1 | 6.5 | 4.4 | 27.7 | 1 | Never | 0 | 2 | 9.6 | 0 | 4.1 | -0.62 | Insulin_requiring | 17.36 | null | 4.3 | 15 | 91.1 | 1 | 0 | 1 | 0 | 0 | null | 0 | 1 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 1 | High | 0 | 3 | 0 | 0 | 0 | 1 | Libre2 | 1 | 0 | 7 | 1 | 0 | 3.81 | 10 | 8.6 | 9.1 | 0 | HC-END-002 | 42 | 2026-05-29T12:51:29Z |
HC002-0000056 | Female | 45.5 | 5.2 | 50.8 | White | Private | 33.4 | 85.5 | 160.1 | 69.9 | 0.909 | 37.9 | 0.8 | 9.1 | 7.1 | 0 | 0 | 216.8 | 330.4 | 40.8 | 21.83 | 109.2 | 4.4 | 57 | 167.4 | 70.8 | 21.5 | 375.6 | 145.9 | 5.9 | 4.57 | 56.3 | 41.6 | 44.8 | 2.9 | 26.9 | 4.45 | 165 | 76 | 1 | Thiazide | Dual | 0 | 0 | 0 | 0 | null | 0 | 0 | 0 | 0 | 0 | null | 0 | 0 | 0 | 0 | 0 | null | 0 | 0 | null | 0 | 0 | 0 | 0 | null | 0 | 0 | 0 | 0 | 68.9 | 4 | Low_carb | 78.6 | 1,516 | 24.4 | 24.1 | 11.5 | Mixed | 5 | 73 | 8.5 | 29.7 | 8.3 | 3.5 | 16.7 | 1 | Former | 9 | 5 | 5.9 | 1 | -6.6 | -1.98 | Uncontrolled | 21.83 | null | 10.1 | 43.2 | 25.7 | 0 | 0 | 1 | 0 | 0 | null | 0 | 1 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | null | 1 | 18 | 0 | 0 | 2 | 1 | DexcomG7 | 1 | 1 | 4 | 1 | 0 | 4.44 | 4.5 | 6.4 | 9.5 | 0 | HC-END-002 | 42 | 2026-05-29T12:51:29Z |
HC002-0000057 | Male | 65.8 | 29.9 | 90 | Hispanic | Private | 26 | 83.7 | 179.6 | 75 | 0.901 | 20.8 | 2.6 | 6 | 5.5 | 1 | 0 | 93.9 | 158.4 | 43.7 | 10.13 | 0 | 0.1 | 0.7 | 167.7 | 96.4 | 41.2 | 150.6 | 126.5 | 6.4 | 5.04 | 87.6 | 56.1 | 45.1 | 13.1 | 23.8 | 1.38 | 136 | 90 | 1 | Thiazide | Triple | 0 | 0 | 0 | 0 | null | 0 | 0 | 0 | 0 | 0 | null | 0 | 0 | 0 | 0 | 0 | null | 0 | 1 | Glipizide_10mg | 5 | 1.4 | 0 | 0 | null | 0 | 0 | 0 | 0 | 96.8 | 6 | Western | 39.2 | 2,398 | 54.1 | 16.9 | 14.7 | null | 0 | 0 | 10.9 | 21.6 | 4 | 3.8 | 31.1 | 1 | Never | 0 | 3 | 5.6 | 0 | -2.8 | -0.58 | Insulin_requiring | 10.13 | PDR | 21.7 | 41.2 | 228.4 | 1 | 0 | 1 | 0 | 1 | Peripheral | 3 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 1 | Moderate | 0 | 3 | 0 | 0 | 3 | 1 | DexcomG7 | 1 | 0 | 5 | 1 | 1 | 2.06 | 8.4 | 6 | 3.2 | 0 | HC-END-002 | 42 | 2026-05-29T12:51:29Z |
HC002-0000058 | Female | 30 | 25 | 55 | White | Medicaid | 31.8 | 84.6 | 163.2 | 67.6 | 0.901 | 37 | 1.9 | 5.5 | 5.5 | 1 | 0 | 129.7 | 262 | 28.2 | 9.02 | 13 | 0.7 | 9.3 | 153 | 65.1 | 39.1 | 244.1 | 113.9 | 6 | 3.24 | 77.2 | 52.2 | 73.2 | 5.2 | 49.6 | 1.34 | 168 | 85 | 1 | CCB | Insulin_based | 1 | 1,000 | 0.94 | 1 | Dapagliflozin_10mg | 1.15 | 2.4 | 1.2 | 0 | 0 | null | 0 | 0 | 0 | 0 | 0 | null | 0 | 0 | null | 0 | 0 | 0 | 1 | Basal_only | 25.2 | 25.6 | 2.74 | 5.9 | 68.5 | 6 | Mixed | 42.4 | 1,727 | 36.9 | 18.6 | 10.3 | null | 0 | 0 | 6.5 | 18.5 | 8.5 | 5.8 | 42.2 | 1 | Never | 0 | 5 | 1.4 | 1 | -0.7 | -1.17 | Uncontrolled | 9.02 | DME | 11.6 | 42.5 | 1,602 | 0 | 1 | 1 | 0 | 1 | Autonomic | 5 | 0 | 1 | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | null | 0 | 2 | 1 | 0 | 4 | 1 | DexcomG7 | 1 | 0 | 3 | 2 | 0 | 5.08 | 5 | 8.6 | 6.8 | 1 | HC-END-002 | 42 | 2026-05-29T12:51:29Z |
HC002-0000059 | Male | 42.6 | 24.6 | 67.1 | White | Medicare | 34.5 | 106 | 175.3 | 82 | 0.998 | 28 | 5 | 9 | 7.3 | 0 | 0 | 124.5 | 251 | 23.7 | 7.28 | 13.4 | 0.84 | 8.6 | 196.9 | 100.1 | 43.5 | 266.2 | 153.4 | 5.1 | 11.04 | 49.8 | 40.3 | 32.1 | 11 | 13.5 | 1.88 | 167 | 96 | 1 | Beta_blocker | Dual | 1 | 2,000 | 0.41 | 0 | null | 0 | 0 | 0 | 0 | 1 | Semaglutide_2.0mg | 1.34 | 3 | 0 | 0 | 0 | null | 0 | 0 | null | 0 | 0 | 0 | 1 | Basal_bolus | 31.7 | 62.2 | 1.29 | 0.1 | 67.5 | 8 | Mediterranean | 73.6 | 2,203 | 34.9 | 17.6 | 4.8 | null | 0 | 7 | 7.3 | 26.9 | 5.5 | 3.2 | 55.8 | 1 | Never | 0 | 4 | 4.6 | 0 | -0.4 | 0.36 | Uncontrolled | 7.28 | Moderate_NPDR | 8.3 | 55.9 | 349.8 | 0 | 1 | 1 | 0 | 1 | Autonomic | 6 | 1 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 1 | Moderate | 0 | 2 | 1 | 0 | 1 | 0 | null | 0 | 0 | 5 | 0 | 0 | 3.04 | 2.9 | 5.2 | 8.2 | 0 | HC-END-002 | 42 | 2026-05-29T12:51:29Z |
HC002-0000060 | Male | 31.8 | 30 | 61.8 | White | Private | 37.4 | 111.7 | 172.8 | 87.5 | 0.912 | 34.6 | 2.8 | 9.1 | 5.5 | 1 | 0 | 187.1 | 248.9 | 40.5 | 18.73 | 30.7 | 1.18 | 14.2 | 200.9 | 50 | 28.7 | 910.9 | 172.2 | 6.4 | 5.28 | 120.8 | 69.8 | 54.7 | 2.6 | 21 | 2.56 | 137 | 84 | 1 | Combination | Insulin_based | 1 | 2,000 | 0.94 | 0 | null | 0 | 0 | 0 | 0 | 1 | Tirzepatide_10mg | 0.66 | 4 | 0 | 1 | 0 | null | 0 | 0 | null | 0 | 0 | 0 | 1 | Premixed | 27.5 | 28.2 | 3.09 | 2.6 | 55.1 | 8 | DASH | 45.5 | 2,039 | 42.4 | 14.9 | 11.3 | Resistance | 0 | 29 | 6.3 | 17.8 | 6.9 | 3.1 | 21.8 | 1 | Never | 0 | 1 | 4.1 | 0 | -0.9 | -0.99 | Complication_burden | 18.73 | PDR | 13.1 | 57.3 | 285.3 | 1 | 0 | 1 | 0 | 0 | null | 0 | 1 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 1 | Moderate | 0 | 2 | 1 | 0 | 1 | 0 | null | 1 | 0 | 3 | 1 | 0 | 1.8 | 5.3 | 7.3 | 7.1 | 0 | HC-END-002 | 42 | 2026-05-29T12:51:29Z |
HC002-0000061 | Female | 42.1 | 12 | 54.1 | White | Medicaid | 36.2 | 84.5 | 152.7 | 76.6 | 0.911 | 42.1 | 3.8 | 9.2 | 9.2 | 0 | 1 | 150.9 | 237.2 | 31.5 | 11.72 | 76.7 | 2.98 | 37.7 | 222.2 | 96.8 | 45.3 | 400.6 | 176.9 | 5.5 | 5.54 | 68.5 | 54.3 | 87.7 | 6 | 34.5 | 2.03 | 149 | 87 | 1 | ARB | Dual | 0 | 0 | 0 | 0 | null | 0 | 0 | 0 | 0 | 0 | null | 0 | 0 | 0 | 0 | 0 | null | 0 | 0 | null | 0 | 0 | 0 | 0 | null | 0 | 0 | 0 | 0 | 94.6 | 5 | Western | 30.1 | 1,729 | 41.3 | 10.5 | 15.5 | Mixed | 7 | 68 | 4 | 27.6 | 5.8 | 5 | 35.1 | 1 | Never | 0 | 0 | 5.1 | 1 | -4 | 0.07 | Insulin_requiring | 11.72 | Moderate_NPDR | 6 | 106.9 | 98.7 | 1 | 0 | 0 | 0 | 0 | null | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 1 | Moderate | 0 | 6 | 0 | 0 | 4 | 1 | Libre2 | 0 | 0 | 5 | 2 | 0 | 0 | 4.8 | 6.5 | 7.1 | 0 | HC-END-002 | 42 | 2026-05-29T12:51:29Z |
HC002-0000062 | Male | 55 | 11.1 | 66.1 | Other | Medicare | 32.8 | 93.3 | 168.6 | 80.3 | 0.95 | 26.7 | 3.1 | 7.6 | 5.5 | 1 | 0 | 115.1 | 193.4 | 90.2 | 25 | 82.4 | 4.07 | 44.3 | 152.4 | 62.6 | 20 | 349 | 132.4 | 4.6 | 5.09 | 50.3 | 34.7 | 69.8 | 12.7 | 26.9 | 2.75 | 155 | 77 | 1 | CCB | Monotherapy | 1 | 1,500 | 1.48 | 0 | null | 0 | 0 | 0 | 0 | 1 | Dulaglutide_1.5mg | 0.87 | 3.4 | 0 | 0 | 0 | null | 0 | 0 | null | 0 | 0 | 0 | 0 | null | 0 | 0 | 0 | 0 | 86.6 | 5 | Western | 6.8 | 1,785 | 42.4 | 8 | 15.9 | Mixed | 3 | 77 | 10.6 | 30.9 | 8.6 | 6.7 | 14.3 | 1 | Former | 3.3 | 3 | 4.5 | 1 | -4.4 | -0.46 | Complication_burden | 25 | null | 19.5 | 52.5 | 394.2 | 0 | 1 | 1 | 0 | 0 | null | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 0 | null | 0 | 3 | 0 | 0 | 5 | 0 | null | 0 | 0 | 6 | 2 | 0 | 2.08 | 6.4 | 8.3 | 7.4 | 0 | HC-END-002 | 42 | 2026-05-29T12:51:29Z |
HC002-0000063 | Female | 49.8 | 9.9 | 59.8 | White | Private | 28 | 68.4 | 156.2 | 65 | 0.775 | 32 | 3.7 | 10.8 | 9.6 | 0 | 1 | 216.8 | 396.1 | 30.1 | 16.13 | 78.9 | 2.97 | 37.5 | 163.1 | 103.1 | 20 | 199.8 | 143.1 | 5.7 | 6.61 | 81.3 | 56.1 | 72.1 | 10.4 | 62 | 2.15 | 150 | 73 | 1 | ACEi | Dual | 1 | 1,500 | 1.08 | 0 | null | 0 | 0 | 0 | 0 | 0 | null | 0 | 0 | 0 | 0 | 0 | null | 0 | 0 | null | 0 | 0 | 0 | 0 | null | 0 | 0 | 0 | 0 | 83.8 | 4 | Low_carb | 65.9 | 1,581 | 25.8 | 22.6 | 11.4 | null | 0 | 0 | 7 | 15 | 6.5 | 4.7 | 20.3 | 1 | Never | 0 | 3 | 7.1 | 1 | -0.8 | -0.32 | Uncontrolled | 16.13 | null | 7.8 | 33.4 | 211.9 | 1 | 0 | 1 | 0 | 0 | null | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | High | 0 | 5 | 0 | 0 | 2 | 0 | null | 1 | 1 | 3 | 0 | 2 | 2.06 | 5.6 | 7.5 | 3.4 | 0 | HC-END-002 | 42 | 2026-05-29T12:51:29Z |
HC002-0000064 | Female | 49 | 1 | 49.9 | Asian | Uninsured | 28.7 | 71.9 | 158.1 | 65 | 0.887 | 32.6 | 3.4 | 7.7 | 6.3 | 1 | 0 | 163.5 | 234.6 | 35.3 | 14.26 | 145.3 | 6.31 | 76.8 | 244.1 | 149.2 | 30.4 | 322.5 | 213.7 | 3.6 | 3.04 | 74.7 | 60.8 | 47.7 | 6.7 | 29.3 | 2.09 | 113 | 84 | 1 | Combination | Monotherapy | 0 | 0 | 0 | 1 | Canagliflozin_100mg | 0.75 | 2.7 | 2.1 | 0 | 0 | null | 0 | 0 | 0 | 0 | 1 | Linagliptin_5mg | 1.03 | 0 | null | 0 | 0 | 0 | 0 | null | 0 | 0 | 0 | 0 | 72 | 5 | Mediterranean | 68.6 | 1,697 | 35 | 21.6 | 10.3 | Mixed | 2 | 53 | 5.7 | 30.9 | 6.1 | 4.2 | 17.5 | 1 | Former | 12.8 | 1 | 4.4 | 1 | -6.1 | -0.09 | Controlled | 14.26 | null | 7.2 | 68.1 | 101 | 1 | 0 | 0 | 0 | 0 | null | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | High | 0 | 5 | 0 | 0 | 2 | 0 | null | 1 | 0 | 2 | 1 | 1 | 1.3 | 4.2 | 7.9 | 10 | 0 | HC-END-002 | 42 | 2026-05-29T12:51:29Z |
HC002-0000065 | Female | 50.1 | 10.5 | 60.6 | Black | Private | 41.3 | 113.5 | 165.8 | 90.3 | 0.873 | 48.5 | 4.3 | 9.1 | 8 | 0 | 0 | 192.6 | 308.5 | 150 | 25 | 66.4 | 2.61 | 37.1 | 178.7 | 50 | 30.9 | 742.1 | 147.9 | 4.6 | 2.07 | 140.3 | 117.5 | 103.1 | 2.7 | 28.4 | 6.52 | 154 | 73 | 1 | Thiazide | Monotherapy | 1 | 2,000 | 1.09 | 0 | null | 0 | 0 | 0 | 0 | 0 | null | 0 | 0 | 0 | 0 | 0 | null | 0 | 1 | Glimepiride_4mg | 5 | 2.3 | 0 | 0 | null | 0 | 0 | 0 | 0 | 59.3 | 8 | Mixed | 48.4 | 1,857 | 43.3 | 11.5 | 8.3 | Resistance | 0 | 22 | 8.9 | 21 | 8.1 | 3.9 | 21.1 | 1 | Never | 0 | 5 | 6.5 | 1 | -5.7 | -0.43 | Controlled | 25 | Moderate_NPDR | 5.6 | 97.5 | 469.3 | 0 | 1 | 0 | 0 | 1 | Both | 6 | 1 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 1 | High | 0 | 1 | 0 | 0 | 0 | 1 | Libre2 | 1 | 0 | 3 | 4 | 1 | 3.43 | 7.3 | 5.4 | 8.2 | 0 | HC-END-002 | 42 | 2026-05-29T12:51:29Z |
HC002-0000066 | Female | 54.4 | 19 | 73.4 | White | Private | 27.2 | 70.4 | 161 | 65 | 0.846 | 31.2 | 1.1 | 9.4 | 5.9 | 1 | 0 | 175 | 366.9 | 32 | 13.81 | 36.1 | 1.3 | 18.1 | 186.1 | 79 | 44.2 | 314.3 | 141.9 | 5.1 | 8.24 | 98.3 | 80.6 | 106.9 | 4.7 | 38.1 | 1.74 | 162 | 95 | 1 | Thiazide | Dual | 1 | 500 | 0.3 | 1 | Empagliflozin_25mg | 0.5 | 4.4 | 4.4 | 0 | 0 | null | 0 | 0 | 0 | 0 | 0 | null | 0 | 0 | null | 0 | 0 | 0 | 1 | Basal_bolus | 31.8 | 32 | 2.35 | 2.2 | 85.8 | 7 | DASH | 56.8 | 1,435 | 40 | 15.7 | 6.5 | Mixed | 2 | 60 | 6.5 | 21.9 | 7.7 | 5.6 | 52.3 | 1 | Never | 0 | 4 | 5.3 | 1 | -3.7 | -0.79 | Insulin_requiring | 13.81 | Moderate_NPDR | 10 | 56.1 | 530.6 | 0 | 1 | 1 | 0 | 1 | Autonomic | 4 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 1 | Moderate | 0 | 6 | 0 | 0 | 5 | 0 | null | 0 | 0 | 7 | 1 | 1 | 1.83 | 8.5 | 5.3 | 5.4 | 0 | HC-END-002 | 42 | 2026-05-29T12:51:29Z |
HC002-0000067 | Female | 39.9 | 4.7 | 44.6 | White | Medicare | 33.3 | 88.6 | 163.2 | 67.5 | 0.858 | 32.2 | 2.5 | 11.1 | 7.6 | 0 | 0 | 205.5 | 355.3 | 52.5 | 25 | 113.6 | 5.61 | 65.5 | 178.3 | 50 | 20 | 657.2 | 158.3 | 4.2 | 1.97 | 77.6 | 61.1 | 112 | 12.2 | 46.6 | 4.6 | 175 | 90 | 1 | ARB | Triple | 0 | 0 | 0 | 1 | Empagliflozin_25mg | 0.84 | 3 | 4.8 | 0 | 0 | null | 0 | 0 | 0 | 0 | 0 | null | 0 | 0 | null | 0 | 0 | 0 | 1 | Concentrated | 24.7 | 47.7 | 2.46 | 2 | 80.9 | 5 | DASH | 60 | 2,393 | 35.6 | 15.7 | 8.5 | Mixed | 7 | 28 | 10 | 30.9 | 6.4 | 3.2 | 8.8 | 0 | Former | 4 | 4 | 4.3 | 1 | -6.5 | -0.89 | Uncontrolled | 25 | null | 5.9 | 89.3 | 202.5 | 1 | 0 | 0 | 0 | 0 | null | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 1 | Low | 0 | 2 | 0 | 0 | 4 | 0 | null | 1 | 0 | 10 | 2 | 1 | 1.47 | 7.5 | 6.3 | 5.2 | 0 | HC-END-002 | 42 | 2026-05-29T12:51:29Z |
HC002-0000068 | Male | 60.5 | 30 | 90 | Asian | Private | 43.8 | 151.4 | 185.9 | 105.7 | 0.917 | 43.3 | 5.3 | 7.9 | 6.3 | 1 | 0 | 156.2 | 307.7 | 62.6 | 24.16 | 9.1 | 0.41 | 3.8 | 228.1 | 111.3 | 24.2 | 463.1 | 203.9 | 6.3 | 13.78 | 68.9 | 59.5 | 90.5 | 4.7 | 45.6 | 4.22 | 148 | 79 | 1 | ACEi | Complex | 1 | 2,000 | 0.97 | 0 | null | 0 | 0 | 0 | 0 | 0 | null | 0 | 0 | 0 | 0 | 1 | Saxagliptin_5mg | 0.64 | 1 | Glipizide_5mg | 2 | 1.7 | 0 | 0 | null | 0 | 0 | 0 | 0 | 92.5 | 6 | Mediterranean | 80.3 | 2,795 | 36.9 | 20 | 6.7 | Aerobic | 2 | 32 | 7.5 | 18.2 | 5.6 | 1.9 | 23.3 | 1 | Former | 31.5 | 5 | 4.1 | 1 | -12.8 | -0.09 | Insulin_requiring | 24.16 | null | 33.3 | 34.7 | 96.2 | 1 | 0 | 1 | 0 | 1 | Both | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 1 | 1 | Moderate | 1 | 12 | 0 | 0 | 8 | 0 | null | 1 | 0 | 1 | 0 | 1 | 1.52 | 6.6 | 7.9 | 8.6 | 0 | HC-END-002 | 42 | 2026-05-29T12:51:29Z |
HC002-0000069 | Male | 60 | 14.4 | 74.3 | White | Private | 45.1 | 136.2 | 173.7 | 107 | 0.997 | 47.4 | 8.2 | 7.4 | 5.8 | 1 | 0 | 139.8 | 242.8 | 66.6 | 23.01 | 63.3 | 3.5 | 39.8 | 229.5 | 63.3 | 32.3 | 669.9 | 197.3 | 6.3 | 21.44 | 86.8 | 78.3 | 124.9 | 5.1 | 28.6 | 2.76 | 144 | 87 | 1 | Beta_blocker | Insulin_based | 0 | 0 | 0 | 0 | null | 0 | 0 | 0 | 0 | 0 | null | 0 | 0 | 0 | 0 | 0 | null | 0 | 0 | null | 0 | 0 | 0 | 0 | null | 0 | 0 | 0 | 0 | 89.9 | 4 | Mixed | 32.8 | 1,200 | 44.9 | 9 | 12.8 | Mixed | 2 | 51 | 8.9 | 20.2 | 5.4 | 5.4 | 24.6 | 1 | Former | 7 | 4 | 6 | 0 | 0.6 | -1.54 | Uncontrolled | 23.01 | Severe_NPDR | 13.2 | 55.1 | 97.5 | 1 | 0 | 1 | 0 | 0 | null | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 1 | Moderate | 0 | 6 | 0 | 0 | 4 | 0 | null | 1 | 1 | 6 | 1 | 0 | 0.81 | 6 | 7.3 | 7.4 | 0 | HC-END-002 | 42 | 2026-05-29T12:51:29Z |
HC002-0000070 | Male | 56.6 | 17.1 | 73.7 | Other | Medicaid | 31.8 | 107.7 | 184.1 | 80 | 0.957 | 31 | 3.1 | 6 | 5.5 | 1 | 0 | 119.1 | 204.7 | 44.4 | 13.07 | 44 | 2.46 | 27.5 | 227.3 | 162.7 | 31.9 | 163.7 | 195.4 | 5.2 | 6.17 | 80 | 61.8 | 101.9 | 8.1 | 46.2 | 0.92 | 148 | 76 | 1 | Combination | Dual | 0 | 0 | 0 | 0 | null | 0 | 0 | 0 | 0 | 1 | Tirzepatide_10mg | 1.17 | 5.3 | 1 | 0 | 1 | Linagliptin_5mg | 0.7 | 1 | Glimepiride_4mg | 2 | 0.7 | 1 | 0 | null | 0 | 0 | 0 | 0 | 62.1 | 8 | Mixed | 56.1 | 2,167 | 42.1 | 10.8 | 11.6 | Aerobic | 3 | 50 | 5.9 | 24.9 | 8.3 | 3.6 | 28.1 | 1 | Former | 0.4 | 3 | 8.2 | 0 | 7.7 | 0.61 | Controlled | 13.07 | null | 6.1 | 29.5 | 125.8 | 1 | 0 | 1 | 0 | 0 | null | 0 | 1 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 0 | null | 0 | 3 | 0 | 0 | 4 | 0 | null | 0 | 1 | 6 | 3 | 0 | 2 | 7.4 | 8.2 | 7.6 | 0 | HC-END-002 | 42 | 2026-05-29T12:51:29Z |
HC002-0000071 | Male | 58.7 | 13.4 | 72.1 | White | Private | 33.4 | 105.1 | 177.5 | 75 | 0.97 | 30.8 | 1.9 | 10.9 | 8.2 | 0 | 0 | 203.2 | 378 | 43 | 21.59 | 53.4 | 3.68 | 36.6 | 186 | 50 | 20.1 | 954.8 | 165.9 | 6.9 | 15.27 | 99.2 | 63.9 | 300 | 4.2 | 15.3 | 2.23 | 156 | 65 | 1 | CCB | Dual | 1 | 1,000 | 0.75 | 0 | null | 0 | 0 | 0 | 0 | 0 | null | 0 | 0 | 0 | 0 | 0 | null | 0 | 0 | null | 0 | 0 | 0 | 1 | Basal_only | 10 | 13.3 | 1.77 | 3.3 | 94.6 | 8 | Western | 25.3 | 2,294 | 47.5 | 9.1 | 14.4 | Mixed | 5 | 35 | 4 | 33.1 | 7.3 | 1.8 | 10.2 | 0 | Former | 2.5 | 4 | 4 | 0 | 7.2 | -0.32 | Uncontrolled | 21.59 | null | 20.1 | 57.6 | 196.2 | 1 | 0 | 1 | 0 | 1 | Peripheral | 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | null | 0 | 3 | 0 | 0 | 7 | 0 | null | 1 | 0 | 4 | 1 | 2 | 2.04 | 5.1 | 4.7 | 8 | 0 | HC-END-002 | 42 | 2026-05-29T12:51:29Z |
HC002-0000072 | Male | 55.6 | 24.4 | 79.9 | Black | Medicaid | 34.1 | 108.4 | 178.3 | 80.1 | 0.981 | 30.3 | 2.3 | 9.1 | 5.5 | 1 | 0 | 190.1 | 291.5 | 41.3 | 19.37 | 20.9 | 0.75 | 11.7 | 151.8 | 67.7 | 31.9 | 260.9 | 119.9 | 5.3 | 6.99 | 88 | 75.1 | 129.3 | 8.1 | 17.4 | 1.75 | 157 | 80 | 1 | Beta_blocker | Insulin_based | 1 | 1,500 | 1 | 0 | null | 0 | 0 | 0 | 0 | 0 | null | 0 | 0 | 0 | 0 | 1 | Linagliptin_5mg | 0.75 | 1 | Glyburide_5mg | 1 | 1.6 | 0 | 1 | Basal_only | 12 | 17.2 | 3.72 | 2.7 | 80.7 | 10 | Mediterranean | 51.8 | 1,278 | 37 | 20.4 | 6.6 | Mixed | 4 | 45 | 5.5 | 25.9 | 7 | 6.5 | 16.7 | 1 | Never | 0 | 0 | 5.6 | 0 | -0.4 | -0.6 | Controlled | 19.37 | DME | 9.9 | 50.4 | 938.9 | 0 | 1 | 1 | 0 | 0 | null | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | Low | 0 | 3 | 0 | 0 | 5 | 0 | null | 1 | 1 | 7 | 0 | 1 | 2.46 | 7.9 | 3.6 | 7.3 | 0 | HC-END-002 | 42 | 2026-05-29T12:51:29Z |
HC002-0000073 | Female | 75 | 8.8 | 83.8 | Asian | Uninsured | 37.5 | 99.6 | 163 | 78.1 | 0.791 | 45.4 | 1 | 9.1 | 6.2 | 1 | 0 | 122.5 | 186.9 | 29.7 | 8.98 | 118.6 | 4.15 | 55.6 | 258.2 | 125.2 | 54.4 | 392.6 | 203.7 | 7.8 | 19.57 | 62.4 | 40 | 61.6 | 5.4 | 41.2 | 2.22 | 161 | 83 | 1 | Thiazide | Dual | 1 | 1,000 | 0.97 | 0 | null | 0 | 0 | 0 | 0 | 0 | null | 0 | 0 | 0 | 0 | 0 | null | 0 | 0 | null | 0 | 0 | 0 | 1 | Basal_only | 29.5 | 45.9 | 2.16 | 2.2 | 84.9 | 8 | Mixed | 64.7 | 2,014 | 49.1 | 18.7 | 11.8 | Mixed | 5 | 33 | 5.1 | 25.6 | 7.4 | 2.1 | 14.8 | 0 | Never | 0 | 1 | 6.5 | 0 | -3 | -0.24 | Complication_burden | 8.98 | null | 10 | 83.9 | 659.8 | 0 | 1 | 0 | 0 | 1 | Peripheral | 6 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | Moderate | 1 | 12 | 0 | 0 | 0 | 0 | null | 1 | 1 | 3 | 3 | 0 | 3.33 | 3.6 | 5.4 | 2.9 | 0 | HC-END-002 | 42 | 2026-05-29T12:51:29Z |
HC002-0000074 | Male | 51 | 11.2 | 62.1 | White | Medicare | 23.2 | 76.5 | 181.6 | 75 | 0.906 | 17.2 | 3.3 | 13.4 | 12.3 | 0 | 1 | 235.3 | 515.5 | 40.2 | 23.35 | 58.3 | 2.28 | 31.2 | 217.5 | 100.5 | 30.3 | 433.8 | 187.2 | 6.1 | 4.4 | 121.7 | 93.9 | 31 | 9.6 | 26.8 | 1.36 | 126 | 90 | 1 | Thiazide | Dual | 0 | 0 | 0 | 0 | null | 0 | 0 | 0 | 0 | 0 | null | 0 | 0 | 0 | 0 | 1 | Alogliptin_25mg | 0.71 | 1 | Glipizide_10mg | 3 | 2.2 | 1 | 0 | null | 0 | 0 | 0 | 0 | 50.7 | 6 | Western | 51 | 1,932 | 49.5 | 18.3 | 17.9 | null | 0 | 0 | 7.6 | 23.9 | 4.5 | 2.6 | 4.2 | 0 | Never | 0 | 5 | 5.5 | 0 | -2.8 | -0.76 | Uncontrolled | 23.35 | Mild_NPDR | 8.7 | 80.8 | 259.1 | 1 | 0 | 0 | 0 | 0 | null | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | Moderate | 0 | 4 | 0 | 0 | 1 | 1 | Libre3 | 1 | 1 | 5 | 1 | 2 | 4.94 | 2.7 | 5.1 | 5.9 | 0 | HC-END-002 | 42 | 2026-05-29T12:51:29Z |
HC002-0000075 | Male | 48.3 | 3.9 | 52.2 | White | Medicaid | 27.9 | 83.2 | 172.7 | 75 | 0.827 | 24.6 | 1.3 | 8.9 | 8.3 | 0 | 0 | 125.2 | 260.6 | 109.7 | 25 | 141.3 | 5.76 | 71.7 | 167.6 | 50 | 28.7 | 488.8 | 139 | 4.8 | 1.54 | 56.2 | 31.2 | 49 | 6.2 | 20.6 | 3.09 | 152 | 85 | 1 | ARB | Monotherapy | 0 | 0 | 0 | 1 | Empagliflozin_10mg | 0.21 | 1.5 | 5.7 | 0 | 0 | null | 0 | 0 | 0 | 0 | 0 | null | 0 | 1 | Glipizide_5mg | 4 | 2.9 | 0 | 0 | null | 0 | 0 | 0 | 0 | 70.2 | 7 | Western | 28.5 | 2,101 | 40.4 | 8.8 | 14.4 | Mixed | 6 | 42 | 4 | 40.1 | 6.4 | 2.6 | 35.7 | 1 | Never | 0 | 3 | 2 | 0 | 1.8 | -0.51 | Uncontrolled | 25 | null | 6.4 | 111.2 | 211.8 | 1 | 0 | 0 | 0 | 0 | null | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | null | 0 | 2 | 0 | 0 | 2 | 0 | null | 0 | 1 | 4 | 1 | 0 | 4.21 | 7.4 | 4.4 | 8 | 0 | HC-END-002 | 42 | 2026-05-29T12:51:29Z |
HC002-0000076 | Male | 43 | 10.3 | 53.3 | Other | Medicaid | 32.2 | 105.4 | 181 | 75 | 0.994 | 27 | 4.1 | 6.3 | 5.5 | 1 | 0 | 119.5 | 234.7 | 74.1 | 21.87 | 88 | 2.74 | 36.4 | 239.1 | 121.9 | 33.2 | 419.9 | 205.9 | 5 | 6.54 | 200 | 121.3 | 49.8 | 3.8 | 24.3 | 3.43 | 135 | 95 | 1 | Thiazide | Triple | 0 | 0 | 0 | 0 | null | 0 | 0 | 0 | 0 | 0 | null | 0 | 0 | 0 | 0 | 0 | null | 0 | 0 | null | 0 | 0 | 0 | 0 | null | 0 | 0 | 0 | 0 | 74.7 | 4 | Mixed | 43.4 | 2,737 | 39 | 8.3 | 12.1 | null | 0 | 0 | 9.3 | 27.8 | 6.4 | 3.1 | 8 | 1 | Never | 0 | 1 | 6.5 | 0 | -0.6 | -1.08 | Insulin_requiring | 21.87 | null | 17.5 | 67.5 | 53.2 | 1 | 0 | 0 | 0 | 1 | Peripheral | 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | Moderate | 0 | 5 | 0 | 0 | 6 | 0 | null | 0 | 0 | 2 | 1 | 2 | 0.61 | 4.1 | 6 | 8.2 | 1 | HC-END-002 | 42 | 2026-05-29T12:51:29Z |
HC002-0000077 | Male | 39.6 | 3.9 | 43.5 | White | Uninsured | 27.9 | 80 | 169.3 | 75 | 0.887 | 25 | 0.6 | 8.1 | 6.4 | 1 | 0 | 195.6 | 278.4 | 42.5 | 20.53 | 121.3 | 5.21 | 62.1 | 164.6 | 50 | 27.5 | 502.6 | 137.2 | 7.6 | 17.7 | 107.5 | 95.2 | 77.9 | 6.6 | 16.8 | 3.72 | 142 | 71 | 1 | ACEi | Dual | 1 | 1,500 | 1.08 | 0 | null | 0 | 0 | 0 | 0 | 0 | null | 0 | 0 | 0 | 0 | 1 | Linagliptin_5mg | 0.71 | 0 | null | 0 | 0 | 0 | 0 | null | 0 | 0 | 0 | 0 | 85.1 | 5 | Mediterranean | 69 | 2,257 | 42.7 | 27.7 | 9.4 | Mixed | 5 | 57 | 5.8 | 36.5 | 8 | 8.3 | 6.8 | 1 | Never | 0 | 3 | 2.5 | 1 | -17.9 | -0.17 | Complication_burden | 20.53 | null | 10.7 | 81.4 | 87.5 | 1 | 0 | 0 | 0 | 0 | null | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | null | 1 | 15 | 0 | 0 | 8 | 1 | Libre3 | 0 | 1 | 4 | 1 | 0 | 4.05 | 4.7 | 3.7 | 5.8 | 0 | HC-END-002 | 42 | 2026-05-29T12:51:29Z |
HC002-0000078 | Female | 37.1 | 25.8 | 62.9 | White | Private | 34.3 | 90.5 | 162.6 | 75.4 | 0.868 | 35.1 | 2.7 | 6.8 | 5.5 | 1 | 0 | 113.1 | 150 | 62.7 | 17.49 | 11.5 | 1.15 | 9.3 | 238.6 | 112.7 | 27 | 494.3 | 211.6 | 4.6 | 9.8 | 41.9 | 42 | 41 | 8.9 | 52.6 | 1.85 | 186 | 83 | 1 | ARB | Dual | 0 | 0 | 0 | 1 | Empagliflozin_10mg | 0.94 | 2.4 | 4.5 | 0 | 0 | null | 0 | 0 | 0 | 0 | 1 | Linagliptin_5mg | 1.34 | 0 | null | 0 | 0 | 0 | 1 | Premixed | 30.6 | 56.7 | 2.12 | 5.3 | 70.6 | 7 | Mixed | 40.3 | 1,713 | 41.6 | 8 | 8.7 | Mixed | 5 | 53 | 4 | 30.9 | 5 | 3.4 | 35.3 | 1 | Never | 0 | 2 | 2.5 | 0 | -0.6 | -0.45 | Insulin_requiring | 17.49 | Severe_NPDR | 4 | 43.8 | 185.6 | 1 | 0 | 1 | 0 | 1 | Peripheral | 6 | 1 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 0 | null | 1 | 11 | 0 | 0 | 3 | 1 | DexcomG7 | 0 | 0 | 1 | 1 | 1 | 4.32 | 4.1 | 5.3 | 6.7 | 0 | HC-END-002 | 42 | 2026-05-29T12:51:29Z |
HC002-0000079 | Female | 41.3 | 12.2 | 53.5 | White | Private | 32.9 | 85.3 | 161.1 | 69.9 | 0.882 | 37.7 | 3.7 | 7.8 | 5.5 | 1 | 0 | 143 | 208.5 | 23.8 | 8.42 | 72.9 | 3.88 | 41 | 241.2 | 114.9 | 40.5 | 428.7 | 200.7 | 3.5 | 5.1 | 67.8 | 41.3 | 125.4 | 8.3 | 46.9 | 1.37 | 125 | 104 | 1 | CCB | Monotherapy | 1 | 2,000 | 1.27 | 1 | Empagliflozin_25mg | 0.96 | 4 | 7.2 | 0 | 0 | null | 0 | 0 | 0 | 0 | 0 | null | 0 | 0 | null | 0 | 0 | 0 | 1 | Basal_only | 15.4 | 21.2 | 0.76 | 2 | 99.7 | 8 | Mediterranean | 64.4 | 2,215 | 37.6 | 18.4 | 7.7 | null | 0 | 6 | 9.2 | 20.6 | 8.1 | 5.6 | 16 | 1 | Never | 0 | 4 | 2.9 | 0 | 2.4 | -0.29 | Uncontrolled | 8.42 | null | 12.9 | 57.2 | 91.7 | 1 | 0 | 1 | 0 | 1 | Autonomic | 4 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 1 | High | 0 | 1 | 0 | 0 | 4 | 0 | null | 0 | 1 | 3 | 1 | 0 | 3.86 | 7.4 | 4.4 | 9.2 | 0 | HC-END-002 | 42 | 2026-05-29T12:51:29Z |
HC002-0000080 | Female | 51.2 | 12 | 63.1 | White | Medicare | 36.1 | 94.5 | 161.8 | 80.6 | 0.896 | 42.1 | 0 | 7.8 | 6.3 | 1 | 0 | 160 | 343 | 34.7 | 13.71 | 56.4 | 2.63 | 29.7 | 150 | 50 | 49.1 | 651.3 | 100.8 | 6.1 | 8.93 | 103.2 | 95.1 | 27.8 | 6.7 | 48.1 | 2.58 | 146 | 61 | 1 | ARB | Triple | 1 | 1,500 | 1.76 | 1 | Empagliflozin_10mg | 0.75 | 0.9 | 5.1 | 0 | 0 | null | 0 | 0 | 0 | 0 | 0 | null | 0 | 0 | null | 0 | 0 | 0 | 0 | null | 0 | 0 | 0 | 0 | 76.7 | 5 | Mediterranean | 77.4 | 2,147 | 47.6 | 19 | 7.7 | Resistance | 3 | 39 | 9 | 15.8 | 9 | 6.7 | 17.2 | 1 | Never | 0 | 6 | 5.2 | 0 | 0.8 | 0.49 | Uncontrolled | 13.71 | null | 12.7 | 74.1 | 265.6 | 1 | 0 | 0 | 0 | 0 | null | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | null | 0 | 2 | 0 | 0 | 5 | 0 | null | 1 | 0 | 1 | 0 | 0 | 2.17 | 4.6 | 3.9 | 9.8 | 0 | HC-END-002 | 42 | 2026-05-29T12:51:29Z |
HC002-0000081 | Female | 56 | 22.9 | 78.9 | Black | Medicare | 36.5 | 85.8 | 153.3 | 74.9 | 0.788 | 43.4 | 5.5 | 7.5 | 5.5 | 1 | 0 | 92.6 | 188.3 | 67.8 | 15.49 | 8.5 | 1.24 | 7.1 | 207.1 | 74.2 | 46.4 | 432.4 | 160.7 | 4.6 | 13.22 | 60.9 | 52.5 | 24.1 | 9.3 | 19.9 | 4.85 | 132 | 81 | 1 | Combination | Triple | 1 | 2,000 | 1.09 | 0 | null | 0 | 0 | 0 | 0 | 0 | null | 0 | 0 | 0 | 0 | 1 | Saxagliptin_5mg | 0.34 | 0 | null | 0 | 0 | 0 | 1 | Basal_only | 26.4 | 38.3 | 1.99 | 4.4 | 76.6 | 9 | Mediterranean | 96.9 | 1,814 | 41.2 | 34 | 4 | Resistance | 5 | 47 | 8.9 | 22.5 | 4.7 | 2.4 | 17.6 | 1 | Current | 2.2 | 5 | 3.6 | 0 | -0.4 | -0.88 | Uncontrolled | 15.49 | Mild_NPDR | 11.4 | 50.8 | 180.9 | 1 | 0 | 1 | 0 | 1 | Both | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 0 | null | 1 | 10 | 0 | 0 | 5 | 0 | null | 0 | 0 | 5 | 0 | 1 | 4.85 | 9 | 3.8 | 7.5 | 0 | HC-END-002 | 42 | 2026-05-29T12:51:29Z |
HC002-0000082 | Male | 52.6 | 3.6 | 56.2 | Black | Private | 33.2 | 99.5 | 173.1 | 79.7 | 0.956 | 31.4 | 2.3 | 6.2 | 5.7 | 1 | 0 | 101.1 | 179 | 87.5 | 21.84 | 122 | 5.44 | 66.6 | 214.7 | 50 | 33.8 | 1,000 | 180.9 | 7 | 6.63 | 37 | 32.3 | 56.8 | 6.5 | 28.1 | 2.27 | 149 | 70 | 1 | ACEi | Monotherapy | 0 | 0 | 0 | 0 | null | 0 | 0 | 0 | 0 | 0 | null | 0 | 0 | 0 | 0 | 0 | null | 0 | 1 | Glyburide_5mg | 1 | 1.5 | 0 | 0 | null | 0 | 0 | 0 | 0 | 93.2 | 6 | Mediterranean | 67.7 | 1,846 | 27.3 | 20.2 | 9.6 | Mixed | 2 | 50 | 4 | 31.1 | 6.8 | 6 | 37.4 | 1 | Current | 7.4 | 5 | 2.6 | 0 | -0.1 | -0.48 | Controlled | 21.84 | null | 12.6 | 106.3 | 27.2 | 0 | 0 | 0 | 0 | 0 | null | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | null | 1 | 15 | 0 | 0 | 0 | 0 | null | 0 | 1 | 5 | 0 | 1 | 1.54 | 7.7 | 4.3 | 8.7 | 0 | HC-END-002 | 42 | 2026-05-29T12:51:29Z |
HC002-0000083 | Female | 42.8 | 3.7 | 46.5 | White | Medicare | 36.6 | 95.1 | 161.1 | 84.7 | 0.96 | 41.4 | 3.7 | 10.9 | 7.6 | 0 | 0 | 210.4 | 457 | 26.4 | 13.71 | 130.7 | 4.9 | 64.6 | 284.4 | 165.2 | 47.1 | 360.4 | 237.3 | 6.2 | 35.75 | 41.9 | 40.2 | 38.8 | 6.7 | 60.5 | 2.7 | 166 | 80 | 1 | Combination | Dual | 1 | 2,000 | 0.64 | 0 | null | 0 | 0 | 0 | 0 | 1 | Semaglutide_1.0mg | 1.57 | 4.5 | 0 | 0 | 0 | null | 0 | 0 | null | 0 | 0 | 0 | 0 | null | 0 | 0 | 0 | 0 | 87 | 8 | Mixed | 62.3 | 1,397 | 52.2 | 28 | 9.1 | null | 0 | 0 | 7.5 | 24.6 | 7.4 | 5.3 | 15 | 0 | Current | 49.7 | 4 | 6.3 | 0 | 0.5 | -1.39 | Insulin_requiring | 13.71 | null | 8.7 | 59.4 | 197.8 | 1 | 0 | 1 | 0 | 0 | null | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 1 | Moderate | 1 | 14 | 0 | 0 | 5 | 0 | null | 1 | 0 | 5 | 0 | 0 | 4.29 | 6.7 | 7.6 | 7.5 | 0 | HC-END-002 | 42 | 2026-05-29T12:51:29Z |
HC002-0000084 | Male | 62.8 | 30 | 90 | Asian | Private | 28.5 | 98.8 | 186.2 | 75 | 1.063 | 25.9 | 3.4 | 8.9 | 6 | 1 | 0 | 94.9 | 135.8 | 27.8 | 6.51 | 23.1 | 0.97 | 7.8 | 156.8 | 50 | 31.4 | 385.9 | 125.4 | 6.5 | 4.71 | 74.6 | 60 | 27.2 | 6.4 | 15.8 | 1.98 | 159 | 83 | 1 | ACEi | Complex | 1 | 2,000 | 0.84 | 1 | Canagliflozin_300mg | 0.33 | 2.7 | 5 | 0 | 0 | null | 0 | 0 | 0 | 0 | 1 | Saxagliptin_5mg | 0.61 | 0 | null | 0 | 0 | 0 | 1 | Basal_bolus | 42.6 | 61.4 | 2.06 | 3.3 | 72.1 | 7 | Low_carb | 66.2 | 1,724 | 25.7 | 19.1 | 13.4 | Mixed | 6 | 56 | 4 | 25 | 7.8 | 6.1 | 25.7 | 1 | Former | 34.5 | 3 | 5.4 | 0 | 1.7 | -0.07 | Complication_burden | 6.51 | Severe_NPDR | 13 | 37.1 | 758.3 | 0 | 1 | 1 | 0 | 0 | null | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 1 | Moderate | 0 | 2 | 0 | 0 | 5 | 1 | Libre2 | 1 | 0 | 1 | 1 | 2 | 4.25 | 9.4 | 5.9 | 8.3 | 0 | HC-END-002 | 42 | 2026-05-29T12:51:29Z |
HC002-0000085 | Male | 60.9 | 13.1 | 74 | White | Uninsured | 33.5 | 111.5 | 182.3 | 82.5 | 1.019 | 29.2 | 4.3 | 8 | 7.4 | 0 | 0 | 121.4 | 218.9 | 128.7 | 25 | 79.7 | 3.52 | 48.9 | 239.4 | 79.5 | 35.1 | 624.6 | 204.4 | 9.1 | 12.82 | 34.2 | 23.3 | 42.2 | 10.2 | 42.2 | 1.75 | 148 | 92 | 1 | Combination | Triple | 1 | 1,000 | 0.3 | 0 | null | 0 | 0 | 0 | 0 | 0 | null | 0 | 0 | 0 | 0 | 0 | null | 0 | 1 | Glipizide_10mg | 1 | 1.3 | 0 | 0 | null | 0 | 0 | 0 | 0 | 85.4 | 5 | Mixed | 29.9 | 2,019 | 46.8 | 8 | 9.5 | HIIT | 4 | 31 | 5.7 | 24.9 | 4.2 | 2 | 10 | 1 | Current | 16.8 | 4 | 7 | 1 | -9 | -0.41 | Uncontrolled | 25 | Mild_NPDR | 5.8 | 42.6 | 264.5 | 1 | 0 | 1 | 0 | 1 | Autonomic | 4 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 1 | Low | 0 | 2 | 0 | 0 | 3 | 0 | null | 0 | 1 | 4 | 1 | 0 | 3.5 | 4.3 | 6.7 | 6.8 | 0 | HC-END-002 | 42 | 2026-05-29T12:51:29Z |
HC002-0000086 | Male | 50.1 | 12.1 | 62.2 | White | Private | 28.9 | 83.2 | 169.7 | 75 | 0.98 | 26.3 | 2.9 | 9.6 | 5.5 | 1 | 0 | 210.9 | 309 | 38.4 | 20.01 | 64.1 | 2.87 | 37.2 | 185.7 | 91.1 | 25.8 | 343.8 | 159.9 | 4.1 | 10.21 | 35.5 | 23.5 | 36.8 | 8.6 | 56.1 | 2.96 | 172 | 87 | 1 | CCB | Triple | 1 | 2,000 | 1.16 | 0 | null | 0 | 0 | 0 | 0 | 0 | null | 0 | 0 | 0 | 0 | 0 | null | 0 | 1 | Glimepiride_4mg | 1 | 0.4 | 0 | 1 | Basal_only | 37.2 | 61.5 | 4.15 | 3.7 | 70 | 9 | Western | 34.7 | 2,843 | 51.5 | 8 | 18.1 | Resistance | 2 | 37 | 10.8 | 28.4 | 7.2 | 5.3 | 22.1 | 1 | Never | 0 | 3 | 4 | 0 | -3.9 | -0.39 | Insulin_requiring | 20.01 | Mild_NPDR | 6.2 | 68.7 | 163.4 | 1 | 0 | 0 | 0 | 1 | Peripheral | 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | Moderate | 1 | 17 | 1 | 0 | 2 | 0 | null | 0 | 1 | 2 | 0 | 2 | 0.28 | 6.5 | 6 | 5.5 | 0 | HC-END-002 | 42 | 2026-05-29T12:51:29Z |
HC002-0000087 | Female | 44.2 | 0.2 | 44.4 | Hispanic | Private | 38.4 | 101.3 | 162.4 | 87.6 | 0.8 | 42 | 5.3 | 9.2 | 7.4 | 0 | 0 | 197.4 | 311 | 112.3 | 25 | 134.1 | 6.2 | 72.5 | 137.8 | 50 | 43.2 | 558.8 | 94.6 | 4.1 | 5 | 111.2 | 80.1 | 66.1 | 5 | 80.4 | 2.1 | 153 | 66 | 1 | Combination | Dual | 1 | 2,000 | 1.36 | 0 | null | 0 | 0 | 0 | 0 | 0 | null | 0 | 0 | 0 | 0 | 0 | null | 0 | 1 | Glyburide_5mg | 4 | 2.8 | 0 | 0 | null | 0 | 0 | 0 | 0 | 93 | 8 | Mixed | 48.2 | 2,212 | 49.6 | 18.2 | 10.4 | Aerobic | 7 | 56 | 4 | 32.9 | 6.5 | 4.3 | 36.9 | 1 | Former | 13.5 | 1 | 5.4 | 0 | 1.5 | -0.49 | Uncontrolled | 25 | null | 3 | 55.9 | 52.1 | 1 | 0 | 1 | 0 | 0 | null | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | null | 0 | 3 | 0 | 0 | 4 | 1 | DexcomG7 | 0 | 1 | 5 | 1 | 1 | 3.08 | 1.6 | 7.9 | 10 | 0 | HC-END-002 | 42 | 2026-05-29T12:51:29Z |
HC002-0000088 | Male | 58.6 | 7.1 | 65.7 | Other | Private | 38 | 109.6 | 169.8 | 92.3 | 1.003 | 34.1 | 5 | 8.8 | 8.1 | 0 | 0 | 170.2 | 365.3 | 45.9 | 19.31 | 93.9 | 3.88 | 46.9 | 180.4 | 52.7 | 20 | 538.8 | 160.4 | 5.9 | 5.86 | 69.8 | 62.7 | 45.1 | 3.5 | 35.3 | 2.64 | 164 | 76 | 1 | Thiazide | Insulin_based | 0 | 0 | 0 | 0 | null | 0 | 0 | 0 | 0 | 0 | null | 0 | 0 | 0 | 0 | 0 | null | 0 | 0 | null | 0 | 0 | 0 | 0 | null | 0 | 0 | 0 | 0 | 80.2 | 5 | Low_carb | 79.6 | 1,665 | 24.6 | 19.4 | 15.8 | Resistance | 3 | 50 | 6.5 | 33 | 6.5 | 5.9 | 49.5 | 1 | Former | 1.3 | 2 | 7.1 | 0 | -0.1 | -0.75 | Uncontrolled | 19.31 | null | 7.5 | 69.7 | 74 | 1 | 0 | 0 | 0 | 1 | Autonomic | 5 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | null | 0 | 2 | 0 | 0 | 2 | 1 | null | 1 | 0 | 5 | 1 | 1 | 3.97 | 5.1 | 7.6 | 10 | 0 | HC-END-002 | 42 | 2026-05-29T12:51:29Z |
HC002-0000089 | Male | 54.3 | 30 | 84.3 | White | Private | 42.1 | 117.1 | 166.7 | 97 | 0.951 | 39.8 | 7.3 | 9.5 | 9.7 | 0 | 1 | 200.3 | 417 | 49.3 | 24.39 | 12.8 | 0.1 | 1.9 | 185.1 | 52.9 | 32.5 | 498.6 | 152.6 | 8.9 | 14.84 | 61.1 | 36.7 | 49.7 | 8.8 | 25.9 | 2.76 | 173 | 88 | 1 | CCB | Dual | 0 | 0 | 0 | 0 | null | 0 | 0 | 0 | 0 | 1 | Dulaglutide_1.5mg | 1.02 | 6.6 | 0 | 1 | 0 | null | 0 | 0 | null | 0 | 0 | 0 | 0 | null | 0 | 0 | 0 | 0 | 84.8 | 4 | Western | 53.1 | 2,372 | 42.6 | 13.5 | 13.7 | null | 0 | 0 | 7.3 | 18 | 9.3 | 4.8 | 9 | 1 | Never | 0 | 9 | 2.9 | 0 | -2 | 1.1 | Uncontrolled | 24.39 | PDR | 16 | 20.1 | 808.4 | 0 | 1 | 1 | 0 | 0 | null | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 1 | High | 1 | 5 | 0 | 0 | 0 | 0 | null | 1 | 0 | 4 | 0 | 1 | 2.87 | 3.6 | 7.7 | 6.9 | 0 | HC-END-002 | 42 | 2026-05-29T12:51:29Z |
HC002-0000090 | Male | 34.6 | 23.9 | 58.5 | White | Private | 36.1 | 119.9 | 182.2 | 82.8 | 0.994 | 30.9 | 4.1 | 8.6 | 6.7 | 1 | 0 | 161.2 | 224.3 | 33.9 | 13.47 | 28.7 | 0.1 | 3.7 | 144.8 | 50 | 46.1 | 411.9 | 98.6 | 8.4 | 8 | 54.5 | 37.8 | 63.7 | 4.9 | 25.7 | 2.57 | 104 | 96 | 1 | ACEi | Dual | 1 | 1,000 | 1.34 | 0 | null | 0 | 0 | 0 | 0 | 0 | null | 0 | 0 | 0 | 0 | 1 | Linagliptin_5mg | 0.45 | 0 | null | 0 | 0 | 0 | 1 | Basal_bolus | 27.1 | 34 | 1.11 | 4.1 | 54.5 | 7 | Mediterranean | 76.5 | 2,043 | 39.6 | 26.8 | 7.9 | Mixed | 5 | 59 | 9.8 | 29.7 | 6.5 | 7.3 | 17.3 | 1 | Never | 0 | 1 | 4.2 | 0 | -0.1 | -0.38 | Complication_burden | 13.47 | PDR | 6.8 | 41.1 | 143.7 | 1 | 0 | 1 | 0 | 1 | Autonomic | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | null | 1 | 12 | 0 | 0 | 1 | 0 | null | 1 | 0 | 3 | 0 | 1 | 2.68 | 8 | 6.1 | 7.6 | 1 | HC-END-002 | 42 | 2026-05-29T12:51:29Z |
HC002-0000091 | Male | 51.2 | 7.3 | 58.5 | Hispanic | Private | 43.8 | 116.6 | 163.1 | 104.1 | 0.922 | 46.6 | 8.4 | 9.5 | 9.3 | 0 | 1 | 188.4 | 287.3 | 73.8 | 25 | 100.7 | 4.58 | 55 | 196.9 | 50 | 28.1 | 760.2 | 168.8 | 7.7 | 10.12 | 42.3 | 25.6 | 128.8 | 5.6 | 34.7 | 2.83 | 150 | 113 | 1 | CCB | Dual | 0 | 0 | 0 | 0 | null | 0 | 0 | 0 | 0 | 0 | null | 0 | 0 | 0 | 0 | 0 | null | 0 | 0 | null | 0 | 0 | 1 | 0 | null | 0 | 0 | 0 | 0 | 87.1 | 7 | Western | 49.6 | 2,425 | 43.1 | 18.4 | 17.1 | null | 0 | 0 | 4.4 | 20.6 | 7.3 | 5.2 | 60 | 1 | Former | 10.2 | 3 | 7.5 | 0 | 4.5 | -0.22 | Uncontrolled | 25 | null | 6.4 | 58 | 817.3 | 0 | 1 | 1 | 0 | 0 | null | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 1 | Low | 1 | 13 | 0 | 0 | 1 | 0 | null | 0 | 1 | 2 | 1 | 0 | 2.28 | 8.7 | 6.4 | 7.2 | 0 | HC-END-002 | 42 | 2026-05-29T12:51:29Z |
HC002-0000092 | Female | 55.1 | 15.1 | 70.2 | Asian | Private | 27.5 | 75.4 | 165.4 | 65 | 0.85 | 27.9 | 2.9 | 9.6 | 7.7 | 0 | 0 | 163.3 | 299.7 | 75.5 | 25 | 49.8 | 2.63 | 28 | 221.4 | 84.6 | 34.9 | 509.6 | 186.5 | 4.1 | 2.36 | 100.1 | 75.1 | 137.9 | 20.2 | 12.2 | 1.5 | 130 | 93 | 1 | Thiazide | Insulin_based | 1 | 2,000 | 0.62 | 0 | null | 0 | 0 | 0 | 0 | 0 | null | 0 | 0 | 0 | 0 | 0 | null | 0 | 0 | null | 0 | 0 | 0 | 1 | Basal_bolus | 23.3 | 37.9 | 0.5 | 2.7 | 70.2 | 8 | Western | 33.2 | 1,702 | 59.1 | 8 | 12.2 | Aerobic | 0 | 42 | 7.9 | 17.5 | 6.7 | 4.1 | 30.7 | 1 | Current | 28.5 | 3 | 5.5 | 0 | 3.4 | -1.08 | Uncontrolled | 25 | Severe_NPDR | 6.4 | 78.6 | 482.2 | 0 | 1 | 0 | 0 | 0 | null | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 1 | 1 | High | 0 | 4 | 0 | 0 | 8 | 0 | null | 0 | 1 | 4 | 2 | 2 | 2.06 | 5.7 | 3.9 | 6.9 | 0 | HC-END-002 | 42 | 2026-05-29T12:51:29Z |
HC002-0000093 | Male | 41.2 | 6.7 | 47.9 | White | Private | 41.7 | 125.2 | 173.2 | 102.9 | 0.97 | 41.4 | 2.6 | 8.7 | 7.7 | 0 | 0 | 159.2 | 215.7 | 24.3 | 9.53 | 104.8 | 4.4 | 52.7 | 194.1 | 133.8 | 45.2 | 75.2 | 148.9 | 5.4 | 11.87 | 45.7 | 33.4 | 74.7 | 7.9 | 48.6 | 1.46 | 135 | 71 | 1 | Combination | Monotherapy | 1 | 1,000 | 1.41 | 0 | null | 0 | 0 | 0 | 0 | 0 | null | 0 | 0 | 0 | 0 | 0 | null | 0 | 0 | null | 0 | 0 | 0 | 0 | null | 0 | 0 | 0 | 0 | 79.6 | 6 | Mixed | 63.4 | 2,778 | 43.2 | 16.3 | 11.1 | null | 0 | 0 | 7.3 | 29.2 | 7.1 | 4.2 | 20.1 | 1 | Former | 15.8 | 2 | 5.2 | 0 | 1.3 | 0.13 | Controlled | 9.53 | null | 12.1 | 73 | 146.8 | 1 | 0 | 0 | 0 | 0 | null | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 1 | Low | 0 | 5 | 0 | 0 | 1 | 0 | null | 0 | 0 | 7 | 1 | 0 | 2.67 | 10 | 5 | 7 | 0 | HC-END-002 | 42 | 2026-05-29T12:51:29Z |
HC002-0000094 | Male | 54.3 | 8.6 | 62.9 | White | Private | 32.6 | 98 | 173.5 | 77.6 | 0.975 | 28 | 6.7 | 8 | 6.7 | 1 | 0 | 129.3 | 232 | 31.5 | 10.06 | 103.9 | 4.55 | 57.6 | 164.4 | 50 | 39.4 | 619.2 | 125 | 5.2 | 8.21 | 48.7 | 33.1 | 69.9 | 13.6 | 11.1 | 2.16 | 175 | 83 | 1 | ARB | Monotherapy | 1 | 1,000 | 1.1 | 0 | null | 0 | 0 | 0 | 0 | 0 | null | 0 | 0 | 0 | 0 | 0 | null | 0 | 0 | null | 0 | 0 | 0 | 0 | null | 0 | 0 | 0 | 0 | 81.9 | 5 | Mixed | 51.2 | 1,836 | 44.7 | 8 | 12.1 | Resistance | 3 | 40 | 4.1 | 26.6 | 7.5 | 4.7 | 19.4 | 1 | Never | 0 | 4 | 5.4 | 1 | -10.7 | -0.47 | Insulin_requiring | 10.06 | null | 13.2 | 64.2 | 1,133.5 | 0 | 1 | 0 | 0 | 0 | null | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | null | 1 | 9 | 0 | 0 | 3 | 0 | null | 1 | 0 | 4 | 0 | 0 | 4.48 | 4.5 | 8.1 | 9.3 | 1 | HC-END-002 | 42 | 2026-05-29T12:51:29Z |
HC002-0000095 | Male | 34.5 | 6.2 | 40.8 | Black | Private | 32.5 | 102.9 | 177.9 | 77.8 | 0.99 | 26.9 | 1.9 | 10.8 | 6.2 | 1 | 0 | 245.1 | 447.6 | 63.3 | 25 | 99.6 | 4.04 | 53 | 179.4 | 66.6 | 22.6 | 450.5 | 156.7 | 5.3 | 6.64 | 96.9 | 61.8 | 54.7 | 5.7 | 22.2 | 2.18 | 140 | 85 | 1 | ACEi | Monotherapy | 1 | 1,000 | 1.34 | 1 | Dapagliflozin_10mg | 0.77 | 0.6 | 5.1 | 0 | 0 | null | 0 | 0 | 0 | 0 | 0 | null | 0 | 0 | null | 0 | 0 | 0 | 1 | Basal_only | 49.5 | 62.6 | 2.61 | 4.8 | 95.3 | 9 | Western | 48.2 | 1,734 | 46.6 | 8 | 14.8 | Aerobic | 5 | 52 | 8.7 | 38.4 | 7.9 | 4 | 23.2 | 1 | Never | 0 | 1 | 7.9 | 0 | -3.1 | -0.13 | Complication_burden | 25 | Mild_NPDR | 3.5 | 84.6 | 429.2 | 0 | 1 | 0 | 0 | 0 | null | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 1 | Moderate | 0 | 3 | 0 | 0 | 3 | 1 | Libre3 | 1 | 1 | 6 | 1 | 1 | 1.82 | 3.8 | 5.3 | 4.6 | 0 | HC-END-002 | 42 | 2026-05-29T12:51:29Z |
HC002-0000096 | Female | 68 | 3.5 | 71.6 | White | Private | 32.3 | 88.6 | 165.5 | 71.3 | 0.825 | 34.7 | 4.4 | 7.6 | 6.9 | 1 | 0 | 180.7 | 282.3 | 35.5 | 15.86 | 121.3 | 5.22 | 65.6 | 184.8 | 95 | 37.7 | 260.9 | 147.1 | 6.9 | 8.54 | 61.9 | 34.3 | 81.2 | 11 | 44.8 | 1.74 | 180 | 76 | 1 | ARB | Dual | 1 | 2,000 | 1.05 | 0 | null | 0 | 0 | 0 | 0 | 0 | null | 0 | 0 | 0 | 0 | 0 | null | 0 | 1 | Glipizide_10mg | 0 | 2 | 0 | 0 | null | 0 | 0 | 0 | 0 | 85.6 | 6 | Western | 49.4 | 1,601 | 51.7 | 17.2 | 14.1 | Resistance | 3 | 46 | 4 | 23.2 | 5.9 | 4.9 | 15.4 | 1 | Never | 0 | 2 | 5.5 | 0 | -1.8 | 0.14 | Controlled | 15.86 | null | 4.2 | 59.9 | 75 | 1 | 0 | 1 | 0 | 0 | null | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | null | 0 | 3 | 0 | 0 | 4 | 0 | null | 0 | 0 | 5 | 2 | 0 | 3.35 | 5.1 | 5.9 | 5.5 | 0 | HC-END-002 | 42 | 2026-05-29T12:51:29Z |
HC002-0000097 | Male | 67 | 11.3 | 78.2 | White | Private | 32.7 | 93.6 | 169.2 | 75 | 0.879 | 31.4 | 2.5 | 9 | 7.5 | 0 | 0 | 208.3 | 325.7 | 29.2 | 15.03 | 57.2 | 3.55 | 41.2 | 193.3 | 113.3 | 35.9 | 220.4 | 157.4 | 5.9 | 5.42 | 49 | 30.6 | 77.3 | 7.2 | 17.9 | 2.45 | 124 | 90 | 1 | ARB | Triple | 1 | 1,000 | 1.25 | 0 | null | 0 | 0 | 0 | 0 | 0 | null | 0 | 0 | 0 | 0 | 0 | null | 0 | 1 | Glipizide_10mg | 2 | 4.1 | 0 | 0 | null | 0 | 0 | 0 | 0 | 82.8 | 5 | Western | 43.6 | 1,399 | 52.3 | 16 | 13.8 | null | 0 | 4 | 8.1 | 19.4 | 7 | 4.5 | 27 | 1 | Former | 3.5 | 1 | 5.6 | 0 | 1 | -0.46 | Controlled | 15.03 | null | 16.3 | 35.5 | 72.9 | 1 | 0 | 1 | 0 | 0 | null | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 0 | 1 | 1 | High | 0 | 2 | 0 | 0 | 2 | 0 | null | 1 | 0 | 7 | 4 | 1 | 0 | 7 | 7.8 | 8.8 | 0 | HC-END-002 | 42 | 2026-05-29T12:51:29Z |
HC002-0000098 | Male | 49 | 9.6 | 58.6 | White | Private | 29.2 | 94.6 | 180 | 75 | 1.057 | 24 | 4.1 | 9.1 | 5.5 | 1 | 0 | 151.6 | 228.3 | 63.8 | 23.86 | 93 | 4.14 | 48.4 | 227.2 | 121.6 | 20 | 427.9 | 207.2 | 6.1 | 4.56 | 28.9 | 12.9 | 129.3 | 8.8 | 21.5 | 3.31 | 128 | 57 | 0 | null | Dual | 1 | 1,000 | 1.54 | 0 | null | 0 | 0 | 0 | 0 | 1 | Liraglutide_1.8mg | 1.65 | 1.1 | 0 | 1 | 1 | Sitagliptin_100mg | 0.52 | 0 | null | 0 | 0 | 0 | 0 | null | 0 | 0 | 0 | 0 | 94.3 | 7 | Vegan | 66.1 | 2,131 | 51.6 | 20.3 | 7.7 | Aerobic | 1 | 46 | 8.3 | 33.1 | 7 | 7.4 | 24.4 | 1 | Never | 0 | 3 | 5.5 | 0 | 1.1 | -0.81 | Complication_burden | 23.86 | null | 6.8 | 52.5 | 127.2 | 1 | 0 | 1 | 0 | 0 | null | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 0 | null | 0 | 2 | 0 | 0 | 3 | 1 | null | 1 | 0 | 3 | 1 | 1 | 2.06 | 8.1 | 7 | 7.2 | 0 | HC-END-002 | 42 | 2026-05-29T12:51:29Z |
HC002-0000099 | Male | 56.4 | 30 | 86.4 | White | Private | 28.2 | 87.1 | 175.8 | 75 | 1.109 | 22.1 | 1.5 | 7.4 | 5.5 | 1 | 0 | 112.6 | 241.1 | 66.2 | 18.41 | 17.4 | 0.59 | 9.9 | 195.3 | 98.3 | 32.4 | 323 | 162.9 | 7.1 | 5.52 | 85.3 | 64.8 | 18.5 | 17.4 | 29.5 | 3.75 | 169 | 95 | 1 | ACEi | Dual | 1 | 2,000 | 1.02 | 0 | null | 0 | 0 | 0 | 0 | 0 | null | 0 | 0 | 0 | 0 | 0 | null | 0 | 0 | null | 0 | 0 | 0 | 0 | null | 0 | 0 | 0 | 0 | 45.4 | 5 | DASH | 63 | 2,520 | 44.3 | 18.7 | 7.4 | Aerobic | 4 | 43 | 5.5 | 34.1 | 4.8 | 2.8 | 9.2 | 0 | Never | 0 | 2 | 2.3 | 0 | -1 | -1.8 | Insulin_requiring | 18.41 | DME | 24.4 | 36.5 | 299.6 | 1 | 0 | 1 | 0 | 0 | null | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | null | 0 | 2 | 0 | 0 | 4 | 0 | null | 0 | 0 | 6 | 2 | 1 | 3.8 | 7.8 | 6.5 | 9.5 | 0 | HC-END-002 | 42 | 2026-05-29T12:51:29Z |
HC002-0000100 | Female | 30 | 1.7 | 31.7 | Hispanic | Private | 30.5 | 76.2 | 158.1 | 65 | 0.887 | 34.1 | 2.4 | 7.1 | 5.5 | 1 | 0 | 161 | 265.6 | 29.1 | 11.56 | 151.3 | 5.53 | 74.3 | 131.7 | 55.4 | 31.3 | 224.9 | 100.4 | 3.1 | 5.04 | 66.7 | 48.1 | 51.6 | 6.6 | 31.1 | 4.15 | 139 | 77 | 1 | Combination | Dual | 1 | 2,000 | 1.21 | 0 | null | 0 | 0 | 0 | 0 | 0 | null | 0 | 0 | 0 | 0 | 0 | null | 0 | 1 | Glimepiride_4mg | 2 | 1.9 | 0 | 1 | Basal_bolus | 25.1 | 37.8 | 3.53 | 5.2 | 57.4 | 8 | DASH | 77 | 1,885 | 42.3 | 19.2 | 8.9 | Resistance | 4 | 52 | 4 | 28.7 | 5.7 | 3.6 | 13.9 | 0 | Current | 10.4 | 2 | 6.5 | 0 | 3.6 | -0.63 | Complication_burden | 11.56 | null | 2.1 | 79.3 | 42.5 | 1 | 0 | 0 | 0 | 0 | null | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 1 | Moderate | 0 | 2 | 0 | 0 | 3 | 0 | null | 0 | 0 | 6 | 3 | 1 | 4.21 | 5.5 | 6 | 7 | 1 | HC-END-002 | 42 | 2026-05-29T12:51:29Z |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.